Innovation, Sciences et Développement économique Canada
Office de la Propriété Intellectuelle du Canada

Innovation, Science and Economic Development Canada
Canadian Intellectual Property Office

CA 3141003 A1 2020/12/24

(21) 3 141 003

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2020/06/18
(87) Date publication PCT/PCT Publication Date: 2020/12/24
(85) Entrée phase nationale/National Entry: 2021/12/08
(86) N° demande PCT/PCT Application No.: IB 2020/055712
(87) N° publication PCT/PCT Publication No.: 2020/255020
(30) Priorité/Priority: 2019/06/18 (US62/862,731)

(51) Cl.Int./Int.Cl. *A61K 39/12* (2006.01), *A61K 39/39* (2006.01), *A61P 31/20* (2006.01), *C07D 405/04* (2006.01), *C07D 405/10* (2006.01), *C07D 405/14* (2006.01)

(71) Demandeur/Applicant:
JANSSEN SCIENCES IRELAND UNLIMITED COMPANY, IE

(72) Inventeurs/Inventors:
HORTON, HELEN, BE;
VAN BRANDT, SVEN FRANCISCUS ANNA, BE;
VAN GULCK, ELLEN ROSALIE A, BE;
VAN DONGEN, MARIA JOHANNA PETRONELLA, BE;
MC GOWAN, DAVID CRAIG, BE

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : ASSOCIATION DE VACCINS CONTRE LE VIRUS DE L'HEPATITE B (VHB) ET D'INHIBITEURS DE PD-L1
(54) Title: COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORS



FIG. 1A

(57) Abrégé/Abstract:
Therapeutic combinations of hepatitis B virus (HBV) vaccines and PD-L1 inhibitors are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations of HBV vaccines and PD-L1 inhibitors are also described. Kits comprising the disclosed therapeutic combinations are also described.

Date Submitted: 2021/12/08

CA App. No.: 3141003

Abstract:

Therapeutic combinations of hepatitis B virus (HBV) vaccines and PD-L1 inhibitors are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations of HBV vaccines and PD-L1 inhibitors are also described. Kits comprising the disclosed therapeutic combinations are also described.

TITLE OF THE INVENTION

Combination of Hepatitis B Virus (HBV) Vaccines and PD-L1 Inhibitors

5

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Application No. 62/862,731 filed on June 18, 2019, the disclosure of which is incorporated herein by reference in its entirety.

10 ## REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name "065814_16WO1 Sequence Listing" and a creation date of June 3, 2020 and having a size of 46 kb. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its
15 entirety.

BACKGROUND OF THE INVENTION

Hepatitis B virus (HBV) is a small 3.2-kb hepatotropic DNA virus that encodes four open reading frames and seven proteins. Approximately 240 million people have chronic hepatitis B
20 infection (chronic HBV), characterized by persistent virus and subvirus particles in the blood for more than 6 months (Cohen et al. J. Viral Hepat. (2011) 18(6), 377-83). Persistent HBV infection leads to T-cell exhaustion in circulating and intrahepatic HBV-specific CD4+ and CD8+ T-cells through chronic stimulation of HBV-specific T-cell receptors with viral peptides and circulating antigens. As a result, T-cell polyfunctionality is decreased (i.e., decreased levels
25 of IL-2, tumor necrosis factor (TNF)-α, IFN-γ, and lack of proliferation).

A safe and effective prophylactic vaccine against HBV infection has been available since the 1980s and is the mainstay of hepatitis B prevention (World Health Organization, Hepatitis B: Fact sheet No. 204 [Internet] 2015 March.). The World Health Organization recommends vaccination of all infants, and, in countries where there is low or intermediate hepatitis B
30 endemicity, vaccination of all children and adolescents (<18 years of age), and of people of

CA 03141003 2021-12-8

certain at risk population categories. Due to vaccination, worldwide infection rates have dropped dramatically. However, prophylactic vaccines do not cure established HBV infection.

Chronic HBV is currently treated with IFN-α and nucleoside or nucleotide analogs, but there is no ultimate cure due to the persistence in infected hepatocytes of an intracellular viral replication intermediate called covalently closed circular DNA (cccDNA), which plays a fundamental role as a template for viral RNAs, and thus new virions. It is thought that induced virus-specific T-cell and B-cell responses can effectively eliminate cccDNA-carrying hepatocytes. Current therapies targeting the HBV polymerase suppress viremia, but offer limited effect on cccDNA that resides in the nucleus and related production of circulating antigen. The most rigorous form of a cure may be elimination of HBV cccDNA from the organism, which has neither been observed as a naturally occurring outcome nor as a result of any therapeutic intervention. However, loss of HBV surface antigens (HBsAg) is a clinically credible equivalent of a cure, since disease relapse can occur only in cases of severe immunosuppression, which can then be prevented by prophylactic treatment. Thus, at least from a clinical standpoint, loss of HBsAg is associated with the most stringent form of immune reconstitution against HBV.

For example, immune modulation with pegylated interferon (pegIFN)-α has proven better in comparison to nucleoside or nucleotide therapy in terms of sustained off-treatment response with a finite treatment course. Besides a direct antiviral effect, IFN-α is reported to exert epigenetic suppression of cccDNA in cell culture and humanized mice, which leads to reduction of virion productivity and transcripts (Belloni et al. J. Clin. Invest. (2012) 122(2), 529-537). However, this therapy is still fraught with side-effects and overall responses are rather low, in part because IFN-α has only poor modulatory influences on HBV-specific T-cells. In particular, cure rates are low (< 10%) and toxicity is high. Likewise, direct acting HBV antivirals, namely the HBV polymerase inhibitors entecavir and tenofovir, are effective as monotherapy in inducing viral suppression with a high genetic barrier to emergence of drug resistant mutants and consecutive prevention of liver disease progression. However, cure of chronic hepatitis B, defined by HBsAg loss or seroconversion, is rarely achieved with such HBV polymerase inhibitors. Therefore, these antivirals in theory need to be administered indefinitely to prevent reoccurrence of liver disease, similar to antiretroviral therapy for human immunodeficiency virus (HIV).

CA 03141003 2021-12-8

Therapeutic vaccination has the potential to eliminate HBV from chronically infected patients (Michel et al. J. Hepatol. (2011) 54(6), 1286-1296). Many strategies have been explored, but to date therapeutic vaccination has not proven successful.

BRIEF SUMMARY OF THE INVENTION

5 Accordingly, there is an unmet medical need in the treatment of hepatitis B virus (HBV), particularly chronic HBV, for a finite well-tolerated treatment with a higher cure rate. The invention satisfies this need by providing therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection. The immunogenic compositions/combinations and methods of the invention can be used to provide therapeutic 10 immunity to a subject, such as a subject having chronic HBV infection.

In a general aspect, the application relates to therapeutic combinations or compositions comprising one or more HBV antigens, or one or more polynucleotides encoding the HBV antigens, and an PD-L1 inhibitor, for use in treating an HBV infection in a subject in need thereof.

In one embodiment, the therapeutic combination comprises:

15 i) at least one of:

a) a truncated HBV core antigen consisting of an amino acid sequence that is at least 95%, such as at least 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 2,

b) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding the truncated HBV core antigen;

20 c) an HBV polymerase antigen having an amino acid sequence that is at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity, and

d) a second non-naturally occurring nucleic acid molecule comprising a second 25 polynucleotide sequence encoding the HBV polymerase antigen; and

ii) a compound of formula (I):

CA 03141003 2021-12-8

(I)

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof.

In formula (I), R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-membered heteroaryl), and a ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H, halogen, C_{1-4}alkyl and C_{1-4}alkyl substituted with one or more F;

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one or more substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, C_{3-6}heterocycle, aryl and heteroaryl;

wherein C_{3-6}heterocycle is optionally substituted with one or more substituent selected from oxo, OH and CO_2H;

with the proviso that R^8 and R^9 are not both H;

or wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle optionally substituted with one or more substituents selected from C_{1-6}alkyl, oxo, OH and CO_2H;

R^{10} is selected from H, CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-$C(O)NH_2$, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-$C(O)N(C_{1-6}alkyl)_2$, $C(=O)NR^xR^y$, SO_2-C_{1-6}alkyl, aryl and heteroaryl;

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-$C(O)NH_2$, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-$C(O)N(C_{1-6}alkyl)_2$, $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl;

X is N or CR^{12};

R^{12} is selected from H, F, Cl, CN, $C(=O)NR^xR^y$, aryl and heteroaryl,

CA 03141003 2021-12-8

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, C(=O)NR^xR^y and SO_2-C_{1-6}alkyl; and

5 R^x and R^y are independently selected from H and C_{1-6}alkyl;

In one embodiment, the truncated HBV core antigen consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, and the HBV polymerase antigen comprises the amino acid sequence of SEQ ID NO: 7.

10 In one embodiment, the therapeutic combination comprises at least one of the HBV polymerase antigen and the truncated HBV core antigen. In certain embodiments, the therapeutic combination comprises the HBV polymerase antigen and the truncated HBV core antigen.

In one embodiment, the therapeutic combination comprises at least one of the first non-naturally occurring nucleic acid molecule comprising the first polynucleotide sequence encoding

15 the truncated HBV core antigen, and the second non-naturally occurring nucleic acid molecule comprising the second polynucleotide sequence encoding the HBV polymerase antigen. In certain embodiments, the first non-naturally occurring nucleic acid molecule further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the truncated HBV core antigen, and the second non-naturally occurring nucleic acid molecule

20 further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the HBV polymerase antigen, preferably, the signal sequence independently comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15, more preferably, the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 14, respectively.

25 In certain embodiments, the first polynucleotide sequence comprises the polynucleotide sequence having at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

In certain embodiments, the second polynucleotide sequence comprises a polynucleotide sequence having at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,

30 99% or 100%, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.

In an embodiment, a therapeutic combination comprises:

CA 03141003 2021-12-8

a) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 95%, such as at least 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 2;

5 b) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having an amino acid sequence that is at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H

10 activity; and

c) a compound of formula (I):

(I)

or a tautomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein R^1 to R^{11} and X are as described above.

15 In certain embodiments, R^1 of formula (I) is an optionally substituted monocyclic or bicyclic ring, preferably R^1 of formula (I) is formula (g-1) (g-1) .

In certain embodiemnts, R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} of formula (I) are independently selected from H and C_{1-4}alkyl.

In certain embodiemnts, R^6 of formula (I) is C_{1-4}alkyl or Cl.

20 In certain embodiemnts, in formula (I), R^6 is Cl, and R^2, R^3, R^4, R^5, R^7 and R^{11} are H.

In certain embodiments, in formula (I), R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with

CA 03141003 2021-12-8

one, two, or three substituents selected from $C_{1\text{-}4}$alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1\text{-}4}$alkyl, aryl and heteroaryl. Preferably, R^8 is H and R^9 is $C_{1\text{-}6}$alkyl substituted with OH and CO_2H.

In certain embodiments, in formula (I), R^8 and R^9 are connected together to form a $C_{3\text{-}6}$heterocycle substituted with OH and CO_2H, preferably the $C_{3\text{-}6}$heterocycle is pyrrolidine.

5 In certain embodiments, in formula (I), R^{10} is selected from H and CN;

In certain embodiments, in formula (I), R^{12} is selected from H, Cl, and CN; and

In certain embodiments, in formula (I), X is N.

Preferably, the therapeutic combination comprises a) a first non-naturally occurring 10 nucleic acid molecule comprising a first polynucleotide sequence encoding an truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; b) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having the amino acid sequence of SEQ ID NO: 7, and (c) a compound selected from the group consisting of the exemplified compounds, 15 particularly compounds 7, 8, 9, 10, 11, 12, 101, 103, 202, 203, and 204 described herein, or a tautomer or stereoisomeric form, or a pharmaceutically acceptable salt thereof.

Preferably, the therapeutic combination comprises a) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; b) a 20 second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having the amino acid sequence of SEQ ID NO: 7, and (c) a compound selected from the group consisting of the exemplified compounds, particularly compounds 205, 207, and 209 described herein, or a tautomer or stereoisomeric form, or a pharmaceutically acceptable salt thereof.

25 Preferably, the therapeutic combination comprises a first non-naturally occurring nucleic acid molecule comprising a polynucleotide sequence having at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3, and a second non-naturally occurring nucleic acid molecule comprising the polynucleotide sequence having at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 30 96%, 97%, 98%, 99% or 100%, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.

More preferably, the therapeutic combination comprises a) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3; b) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence of SEQ ID NO: 5 or 6; and c) a compound selected from the group consisting of the exemplified compounds, particularly compounds 7, 8, 9, 10, 11, 12, 101, 103, 202, 203, and 204 described herein, or a tautomer or stereoisomeric form, or a pharmaceutically salt thereof.

More preferably, the therapeutic combination comprises a) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3; b) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence of SEQ ID NO: 5 or 6; and c) a compound selected from the group consisting of the exemplified compounds, particularly compounds 205, 207, and 209 described herein, or a tautomer or stereoisomeric form, or a pharmaceutically salt thereof.

In an embodiment, each of the first and the second non-naturally occurring nucleic acid molecules is a DNA molecule, preferably the DNA molecule is present on a plasmid or a viral vector.

In another embodiment, each of the first and the second non-naturally occurring nucleic acid molecules is an RNA molecule, preferably an mRNA or a self-replicating RNA molecule.

In some embodiments, each of the first and the second non-naturally occurring nucleic acid molecules is independently formulated with a lipid nanoparticle (LNP).

In another general aspect, the application relates to a kit comprising a therapeutic combination of the application.

The application also relates to a therapeutic combination or kit of the application for use in inducing an immune response against hepatitis B virus (HBV); and use of a therapeutic combination, composition or kit of the application in the manufacture of a medicament for inducing an immune response against hepatitis B virus (HBV). The use can further comprise a combination with another immunogenic or therapeutic agent, preferably another HBV antigen or another HBV therapy. Preferably, the subject has chronic HBV infection.

The application further relates to a therapeutic combination or kit of the application for use in treating an HBV-induced disease in a subject in need thereof; and use of a therapeutic combination or kit of the application in the manufacture of a medicament for treating an HBV-

CA 03141003 2021-12-8

induced disease in a subject in need thereof. The use can further comprise a combination with another therapeutic agent, preferably another anti-HBV antigen. Preferably, the subject has chronic HBV infection, and the HBV-induced disease is selected from the group consisting of advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).

5 The application also relates to a method of inducing an immune response against an HBV or a method of treating an HBV infection or an HBV-induced disease, comprising administering to a subject in need thereof a therapeutic combination according to embodiments of the application.

Other aspects, features and advantages of the invention will be apparent from the 10 following disclosure, including the detailed description of the invention and its preferred embodiments and the appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of preferred 15 embodiments of the present application, will be better understood when read in conjunction with the appended drawings. It should be understood, however, that the application is not limited to the precise embodiments shown in the drawings.

FIG. 1A and **FIG. 1B** show schematic representations of DNA plasmids according to embodiments of the application; **FIG. 1A** shows a DNA plasmid encoding an HBV core antigen 20 according to an embodiment of the application; **FIG. 1B** shows a DNA plasmid encoding an HBV polymerase (pol) antigen according to an embodiment of the application; the HBV core and pol antigens are expressed under control of a CMV promoter with an N-terminal cystatin S signal peptide that is cleaved from the expressed antigen upon secretion from the cell; transcriptional regulatory elements of the plasmid include an enhancer sequence located between the CMV 25 promoter and the polynucleotide sequence encoding the HBV antigen and a bGH polyadenylation sequence located downstream of the polynucleotide sequence encoding the HBV antigen; a second expression cassette is included in the plasmid in reverse orientation including a kanamycin resistance gene under control of an Ampr (bla) promoter; an origin of replication (pUC) is also included in reverse orientation.

30 **FIG. 2A** and **FIG. 2B**. show the schematic representations of the expression cassettes in adenoviral vectors according to embodiments of the application; **FIG. 2A** shows the expression

CA 03141003 2021-12-8

cassette for a truncated HBV core antigen, which contains a CMV promoter, an intron (a fragment derived from the human ApoAI gene - GenBank accession X01038 base pairs 295 – 523, harboring the ApoAI second intron), a human immunoglobulin secretion signal, followed by a coding sequence for a truncated HBV core antigen and a SV40 polyadenylation signal; **FIG. 2B** shows the expression cassette for a fusion protein of a truncated HBV core antigen operably linked to an HBV polymerase antigen, which is otherwise identical to the expression cassette for the truncated HBV core antigen except the HBV antigen.

FIG. 3 shows ELISPOT responses of Balb/c mice immunized with different DNA plasmids expressing HBV core antigen or HBV pol antigen, as described in Example 3; peptide pools used to stimulate splenocytes isolated from the various vaccinated animal groups are indicated in gray scale; the number of responsive T-cells are indicated on the y-axis expressed as spot forming cells (SFC) per 10^6 splenocytes;

DETAILED DESCRIPTION OF THE INVENTION

Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set forth in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set forth fully herein.

It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.

Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific

CA 03141003 2021-12-8

embodiments of the invention described herein. Such equivalents are intended to be encompassed by the invention.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. When used herein the term "comprising" can be substituted with the term "containing" or "including" or sometimes when used herein with the term "having".

When used herein "consisting of" excludes any element, step, or ingredient not specified in the claim element. When used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Any of the aforementioned terms of "comprising", "containing", "including", and "having", whenever used herein in the context of an aspect or embodiment of the application can be replaced with the term "consisting of" or "consisting essentially of" to vary scopes of the disclosure.

As used herein, the conjunctive term "and/or" between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by "and/or," a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or" as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or."

Unless otherwise stated, any numerical value, such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term "about." Thus, a numerical value typically includes ± 10% of the recited value. For example, a concentration of 1 mg/mL includes 0.9 mg/mL to 1.1 mg/mL. Likewise, a concentration range of 1 mg/mL to 10 mg/mL includes 0.9 mg/mL to 11 mg/mL. As used herein, the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise.

CA 03141003 2021-12-8

The phrases "percent (%) sequence identity" or "% identity" or "% identical to" when used with reference to an amino acid sequence describe the number of matches ("hits") of identical amino acids of two or more aligned amino acid sequences as compared to the number of amino acid residues making up the overall length of the amino acid sequences. In other terms, using an alignment, for two or more sequences the percentage of amino acid residues that are the same (e.g. 90%, 91%, 92%, 93%, 94%, 95%, 97%, 98%, 99%, or 100% identity over the full-length of the amino acid sequences) may be determined, when the sequences are compared and aligned for maximum correspondence as measured using a sequence comparison algorithm as known in the art, or when manually aligned and visually inspected. The sequences which are compared to determine sequence identity may thus differ by substitution(s), addition(s) or deletion(s) of amino acids. Suitable programs for aligning protein sequences are known to the skilled person. The percentage sequence identity of protein sequences can, for example, be determined with programs such as CLUSTALW, Clustal Omega, FASTA or BLAST, e.g. using the NCBI BLAST algorithm (Altschul SF, et al (1997), *Nucleic Acids Res.* 25:3389-3402).

As used herein, the terms and phrases "in combination," "in combination with," "co-delivery," and "administered together with" in the context of the administration of two or more therapies or components to a subject refers to simultaneous administration or subsequent administration of two or more therapies or components, such as two vectors, e.g., DNA plasmids, peptides, or a therapeutic combination and an adjuvant. "Simultaneous administration" can be administration of the two or more therapies or components at least within the same day. When two components are "administered together with" or "administered in combination with," they can be administered in separate compositions sequentially within a short time period, such as 24, 20, 16, 12, 8 or 4 hours, or within 1 hour, or they can be administered in a single composition at the same time. "Subsequent administration" can be administration of the two or more therapies or components in the same day or on separate days. The use of the term "in combination with" does not restrict the order in which therapies or components are administered to a subject. For example, a first therapy or component (e.g. first DNA plasmid encoding an HBV antigen) can be administered prior to (e.g., 5 minutes to one hour before), concomitantly with or simultaneously with, or subsequent to (e.g., 5 minutes to one hour after) the administration of a second therapy or component (e.g., second DNA plasmid encoding an HBV antigen), and/or a third therapy or component (e.g., PD-L1 inhibitor). In some embodiments, a first therapy or component (e.g.

first DNA plasmid encoding an HBV antigen), a second therapy or component (e.g., second DNA plasmid encoding an HBV antigen), and a third therapy or component (e.g., PD-L1 inhibitor) are administered in the same composition. In other embodiments, a first therapy or component (e.g. first DNA plasmid encoding an HBV antigen), a second therapy or component (e.g., second DNA plasmid encoding an HBV antigen), and a third therapy or component (e.g., PD-L1 inhibitor) are administered in separate compositions, such as two or three separate compositions.

As used herein, a "non-naturally occurring" nucleic acid or polypeptide, refers to a nucleic acid or polypeptide that does not occur in nature. A "non-naturally occurring" nucleic acid or polypeptide can be synthesized, treated, fabricated, and/or otherwise manipulated in a laboratory and/or manufacturing setting. In some cases, a non-naturally occurring nucleic acid or polypeptide can comprise a naturally-occurring nucleic acid or polypeptide that is treated, processed, or manipulated to exhibit properties that were not present in the naturally-occurring nucleic acid or polypeptide, prior to treatment. As used herein, a "non-naturally occurring" nucleic acid or polypeptide can be a nucleic acid or polypeptide isolated or separated from the natural source in which it was discovered, and it lacks covalent bonds to sequences with which it was associated in the natural source. A "non-naturally occurring" nucleic acid or polypeptide can be made recombinantly or via other methods, such as chemical synthesis.

As used herein, "subject" means any animal, preferably a mammal, most preferably a human, to whom will be or has been treated by a method according to an embodiment of the application. The term "mammal" as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs) such as monkeys or apes, humans, etc., more preferably a human.

As used herein, the term "operably linked" refers to a linkage or a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a regulatory sequence operably linked to a nucleic acid sequence of interest is capable of directing the transcription of the nucleic acid sequence of interest, or a signal sequence operably linked to an amino acid sequence of interest is capable of secreting or translocating the amino acid sequence of interest over a membrane.

CA 03141003 2021-12-8

In an attempt to help the reader of the application, the description has been separated in various paragraphs or sections, or is directed to various embodiments of the application. These separations should not be considered as disconnecting the substance of a paragraph or section or embodiments from the substance of another paragraph or section or embodiments. To the
5 contrary, one skilled in the art will understand that the description has broad application and encompasses all the combinations of the various sections, paragraphs and sentences that can be contemplated. The discussion of any embodiment is meant only to be exemplary and is not intended to suggest that the scope of the disclosure, including the claims, is limited to these examples. For example, while embodiments of HBV vectors of the application (e.g., plasmid
10 DNA or viral vectors) described herein may contain particular components, including, but not limited to, certain promoter sequences, enhancer or regulatory sequences, signal peptides, coding sequence of an HBV antigen, polyadenylation signal sequences, etc. arranged in a particular order, those having ordinary skill in the art will appreciate that the concepts disclosed herein may equally apply to other components arranged in other orders that can be used in HBV vectors of
15 the application. The application contemplates use of any of the applicable components in any combination having any sequence that can be used in HBV vectors of the application, whether or not a particular combination is expressly described. The invention generally relates to a therapeutic combination comprising one or more HBV antigens and at least one PD-L1 inhibitor.

Hepatitis B Virus (HBV)

20 As used herein “hepatitis B virus” or “HBV” refers to a virus of the hepadnaviridae family. HBV is a small (e.g., 3.2 kb) hepatotropic DNA virus that encodes four open reading frames and seven proteins. The seven proteins encoded by HBV include small (S), medium (M), and large (L) surface antigen (HBsAg) or envelope (Env) proteins, pre-Core protein, core protein, viral polymerase (Pol), and HBx protein. HBV expresses three surface antigens, or
25 envelope proteins, L, M, and S, with S being the smallest and L being the largest. The extra domains in the M and L proteins are named Pre-S2 and Pre-S1, respectively. Core protein is the subunit of the viral nucleocapsid. Pol is needed for synthesis of viral DNA (reverse transcriptase, RNaseH, and primer), which takes place in nucleocapsids localized to the cytoplasm of infected hepatocytes. PreCore is the core protein with an N-terminal signal peptide and is proteolytically
30 processed at its N and C termini before secretion from infected cells, as the so-called hepatitis B e-antigen (HBeAg). HBx protein is required for efficient transcription of covalently closed

CA 03141003 2021-12-8

circular DNA (cccDNA). HBx is not a viral structural protein. All viral proteins of HBV have their own mRNA except for core and polymerase, which share an mRNA. With the exception of the protein pre-Core, none of the HBV viral proteins are subject to post-translational proteolytic processing.

5 The HBV virion contains a viral envelope, nucleocapsid, and single copy of the partially double-stranded DNA genome. The nucleocapsid comprises 120 dimers of core protein and is covered by a capsid membrane embedded with the S, M, and L viral envelope or surface antigen proteins. After entry into the cell, the virus is uncoated and the capsid-containing relaxed circular DNA (rcDNA) with covalently bound viral polymerase migrates to the nucleus. During 10 that process, phosphorylation of the core protein induces structural changes, exposing a nuclear localization signal enabling interaction of the capsid with so-called importins. These importins mediate binding of the core protein to nuclear pore complexes upon which the capsid disassembles and polymerase/rcDNA complex is released into the nucleus. Within the nucleus the rcDNA becomes deproteinized (removal of polymerase) and is converted by host DNA repair 15 machinery to a covalently closed circular DNA (cccDNA) genome from which overlapping transcripts encode for HBeAg, HBsAg, Core protein, viral polymerase and HBx protein. Core protein, viral polymerase, and pre-genomic RNA (pgRNA) associate in the cytoplasm and self-assemble into immature pgRNA-containing capsid particles, which further convert into mature rcDNA-capsids and function as a common intermediate that is either enveloped and secreted as 20 infectious virus particles or transported back to the nucleus to replenish and maintain a stable cccDNA pool.

To date, HBV is divided into four serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on the envelope proteins, and into eight genotypes (A, B, C, D, E, F, G, and H) based on the sequence of the viral genome. The HBV genotypes are distributed over different 25 geographic regions. For example, the most prevalent genotypes in Asia are genotypes B and C. Genotype D is dominant in Africa, the Middle East, and India, whereas genotype A is widespread in Northern Europe, sub-Saharan Africa, and West Africa.

HBV Antigens

As used herein, the terms "HBV antigen," "antigenic polypeptide of HBV," "HBV 30 antigenic polypeptide," "HBV antigenic protein," "HBV immunogenic polypeptide," and "HBV immunogen" all refer to a polypeptide capable of inducing an immune response, e.g., a humoral

CA 03141003 2021-12-8

and/or cellular mediated response, against an HBV in a subject. The HBV antigen can be a polypeptide of HBV, a fragment or epitope thereof, or a combination of multiple HBV polypeptides, portions or derivatives thereof. An HBV antigen is capable of raising in a host a protective immune response, e.g., inducing an immune response against a viral disease or
5 infection, and/or producing an immunity (i.e., vaccinates) in a subject against a viral disease or infection, that protects the subject against the viral disease or infection. For example, an HBV antigen can comprise a polypeptide or immunogenic fragment(s) thereof from any HBV protein, such as HBeAg, pre-core protein, HBsAg (S, M, or L proteins), core protein, viral polymerase, or HBx protein derived from any HBV genotype, e.g., genotype A, B, C, D, E, F, G, and/or H, or
10 combination thereof.

(1) HBV Core Antigen

As used herein, each of the terms "HBV core antigen," "HBc" and "core antigen" refers to an HBV antigen capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against an HBV core protein in a subject. Each of the terms "core," "core
15 polypeptide," and "core protein" refers to the HBV viral core protein. Full-length core antigen is typically 183 amino acids in length and includes an assembly domain (amino acids 1 to 149) and a nucleic acid binding domain (amino acids 150 to 183). The 34-residue nucleic acid binding domain is required for pre-genomic RNA encapsidation. This domain also functions as a nuclear import signal. It comprises 17 arginine residues and is highly basic, consistent with its function.
20 HBV core protein is dimeric in solution, with the dimers self-assembling into icosahedral capsids. Each dimer of core protein has four α-helix bundles flanked by an α-helix domain on either side. Truncated HBV core proteins lacking the nucleic acid binding domain are also capable of forming capsids.

In an embodiment of the application, an HBV antigen is a truncated HBV core antigen.
25 As used herein, a "truncated HBV core antigen," refers to an HBV antigen that does not contain the entire length of an HBV core protein, but is capable of inducing an immune response against the HBV core protein in a subject. For example, an HBV core antigen can be modified to delete one or more amino acids of the highly positively charged (arginine rich) C-terminal nucleic acid binding domain of the core antigen, which typically contains seventeen arginine (R) residues. A
30 truncated HBV core antigen of the application is preferably a C-terminally truncated HBV core protein which does not comprise the HBV core nuclear import signal and/or a truncated HBV

CA 03141003 2021-12-8

core protein from which the C-terminal HBV core nuclear import signal has been deleted. In an embodiment, a truncated HBV core antigen comprises a deletion in the C-terminal nucleic acid binding domain, such as a deletion of 1 to 34 amino acid residues of the C-terminal nucleic acid binding domain, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
5 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 amino acid residues, preferably a deletion of all 34 amino acid residues. In a preferred embodiment, a truncated HBV core antigen comprises a deletion in the C-terminal nucleic acid binding domain, preferably a deletion of all 34 amino acid residues.

An HBV core antigen of the application can be a consensus sequence derived from
10 multiple HBV genotypes (e.g., genotypes A, B, C, D, E, F, G, and H). As used herein, "consensus sequence" means an artificial sequence of amino acids based on an alignment of amino acid sequences of homologous proteins, e.g., as determined by an alignment (e.g., using Clustal Omega) of amino acid sequences of homologous proteins. It can be the calculated order of most frequent amino acid residues, found at each position in a sequence alignment, based
15 upon sequences of HBV antigens (e.g., core, pol, etc.) from at least 100 natural HBV isolates. A consensus sequence can be non-naturally occurring and different from the native viral sequences. Consensus sequences can be designed by aligning multiple HBV antigen sequences from different sources using a multiple sequence alignment tool, and at variable alignment positions, selecting the most frequent amino acid. Preferably, a consensus sequence of an HBV antigen is
20 derived from HBV genotypes B, C, and D. The term "consensus antigen" is used to refer to an antigen having a consensus sequence.

An exemplary truncated HBV core antigen according to the application lacks the nucleic acid binding function, and is capable of inducing an immune response in a mammal against at least two HBV genotypes. Preferably a truncated HBV core antigen is capable of inducing a T
25 cell response in a mammal against at least HBV genotypes B, C and D. More preferably, a truncated HBV core antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C and D.

Preferably, an HBV core antigen of the application is a consensus antigen, preferably a consensus antigen derived from HBV genotypes B, C, and D, more preferably a truncated
30 consensus antigen derived from HBV genotypes B, C, and D. An exemplary truncated HBV core consensus antigen according to the application consists of an amino acid sequence that is at

CA 03141003 2021-12-8

least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4. SEQ ID NO: 2 and SEQ ID NO: 4 are core consensus antigens derived from HBV genotypes B, 5 C, and D. SEQ ID NO: 2 and SEQ ID NO: 4 each contain a 34-amino acid C-terminal deletion of the highly positively charged (arginine rich) nucleic acid binding domain of the native core antigen.

In one embodiment of the application, an HBV core antigen is a truncated HBV antigen consisting of the amino acid sequence of SEQ ID NO: 2. In another embodiment, an HBV core 10 antigen is a truncated HBV antigen consisting of the amino acid sequence of SEQ ID NO: 4. In another embodiment, an HBV core antigen further contains a signal sequence operably linked to the N-terminus of a mature HBV core antigen sequence, such as the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. Preferably, the signal sequence has the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15.

15 (2) HBV Polymerase Antigen

As used herein, the term "HBV polymerase antigen," "HBV Pol antigen" or "HBV pol antigen" refers to an HBV antigen capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against an HBV polymerase in a subject. Each of the terms "polymerase," "polymerase polypeptide," "Pol" and "pol" refers to the HBV viral DNA 20 polymerase. The HBV viral DNA polymerase has four domains, including, from the N terminus to the C terminus, a terminal protein (TP) domain, which acts as a primer for minus-strand DNA synthesis; a spacer that is nonessential for the polymerase functions; a reverse transcriptase (RT) domain for transcription; and a RNase H domain.

In an embodiment of the application, an HBV antigen comprises an HBV Pol antigen, or 25 any immunogenic fragment or combination thereof. An HBV Pol antigen can contain further modifications to improve immunogenicity of the antigen, such as by introducing mutations into the active sites of the polymerase and/or RNase domains to decrease or substantially eliminate certain enzymatic activities.

Preferably, an HBV Pol antigen of the application does not have reverse transcriptase 30 activity and RNase H activity, and is capable of inducing an immune response in a mammal against at least two HBV genotypes. Preferably, an HBV Pol antigen is capable of inducing a T

CA 03141003 2021-12-8

cell response in a mammal against at least HBV genotypes B, C and D. More preferably, an HBV Pol antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C and D.

Thus, in some embodiments, an HBV Pol antigen is an inactivated Pol antigen. In an embodiment, an inactivated HBV Pol antigen comprises one or more amino acid mutations in the active site of the polymerase domain. In another embodiment, an inactivated HBV Pol antigen comprises one or more amino acid mutations in the active site of the RNaseH domain. In a preferred embodiment, an inactivated HBV pol antigen comprises one or more amino acid mutations in the active site of both the polymerase domain and the RNaseH domain. For example, the "YXDD" motif in the polymerase domain of an HBV pol antigen that can be required for nucleotide/metal ion binding can be mutated, e.g., by replacing one or more of the aspartate residues (D) with asparagine residues (N), eliminating or reducing metal coordination function, thereby decreasing or substantially eliminating reverse transcriptase function. Alternatively, or in addition to mutation of the "YXDD" motif, the "DEDD" motif in the RNaseH domain of an HBV pol antigen required for Mg2+ coordination can be mutated, e.g., by replacing one or more aspartate residues (D) with asparagine residues (N) and/or replacing the glutamate residue (E) with glutamine (Q), thereby decreasing or substantially eliminating RNaseH function. In a particular embodiment, an HBV pol antigen is modified by (1) mutating the aspartate residues (D) to asparagine residues (N) in the "YXDD" motif of the polymerase domain; and (2) mutating the first aspartate residue (D) to an asparagine residue (N) and the first glutamate residue (E) to a glutamine residue (N) in the "DEDD" motif of the RNaseH domain, thereby decreasing or substantially eliminating both the reverse transcriptase and RNaseH functions of the pol antigen.

In a preferred embodiment of the application, an HBV pol antigen is a consensus antigen, preferably a consensus antigen derived from HBV genotypes B, C, and D, more preferably an inactivated consensus antigen derived from HBV genotypes B, C, and D. An exemplary HBV pol consensus antigen according to the application comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 7, preferably at least 98% identical to SEQ ID NO: 7, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%,

CA 03141003 2021-12-8

99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 7. SEQ ID NO: 7 is a pol consensus antigen derived from HBV genotypes B, C, and D comprising four mutations located in the active sites of the polymerase and RNaseH domains. In particular, the four mutations include mutation of the aspartic acid residues (D) to asparagine residues (N) in the "YXDD" motif of the
5 polymerase domain; and mutation of the first aspartate residue (D) to an asparagine residue (N) and mutation of the glutamate residue (E) to a glutamine residue (Q) in the "DEDD" motif of the RNaseH domain.

In a particular embodiment of the application, an HBV pol antigen comprises the amino acid sequence of SEQ ID NO: 7. In other embodiments of the application, an HBV pol antigen
10 consists of the amino acid sequence of SEQ ID NO: 7. In a further embodiment, an HBV pol antigen further contains a signal sequence operably linked to the N-terminus of a mature HBV pol antigen sequence, such as the amino acid sequence of SEQ ID NO: 7. Preferably, the signal sequence has the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15.

(3) Fusion of HBV Core Antigen and HBV Polymerase Antigen

15 As used herein the term "fusion protein" or "fusion" refers to a single polypeptide chain having at least two polypeptide domains that are not normally present in a single, natural polypeptide.

In an embodiment of the application, an HBV antigen comprises a fusion protein comprising a truncated HBV core antigen operably linked to an HBV Pol antigen, or an HBV Pol
20 antigen operably linked to a truncated HBV core antigen, preferably via a linker.

For example, in a fusion protein containing a first polypeptide and a second heterologous polypeptide, a linker serves primarily as a spacer between the first and second polypeptides. In an embodiment, a linker is made up of amino acids linked together by peptide bonds, preferably from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the
25 20 naturally occurring amino acids. In an embodiment, the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine. Preferably, a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine. Exemplary linkers are polyglycines, particularly (Gly)5, (Gly)8; poly(Gly-Ala), and polyalanines. One exemplary suitable linker as shown in the Examples below is (AlaGly)n, wherein n is an integer
30 of 2 to 5.

CA 03141003 2021-12-8

Preferably, a fusion protein of the application is capable of inducing an immune response in a mammal against HBV core and HBV Pol of at least two HBV genotypes. Preferably, a fusion protein is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C and D. More preferably, the fusion protein is capable of inducing a CD8 T cell
5 response in a human subject against at least HBV genotypes A, B, C and D.

In an embodiment of the application, a fusion protein comprises a truncated HBV core antigen having an amino acid sequence at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4, a linker,
10 and an HBV Pol antigen having an amino acid sequence at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%, identical to SEQ ID NO: 7.

In a preferred embodiment of the application, a fusion protein comprises a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, a linker
15 comprising (AlaGly)n, wherein n is an integer of 2 to 5, and an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 7. More preferably, a fusion protein according to an embodiment of the application comprises the amino acid sequence of SEQ ID NO: 16.

In one embodiment of the application, a fusion protein further comprises a signal sequence operably linked to the N-terminus of the fusion protein. Preferably, the signal sequence has the
20 amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15. In one embodiment, a fusion protein comprises the amino acid sequence of SEQ ID NO: 17.

Additional disclosure on HBV vaccines that can be used for the present invention are described in U.S. Patent Application No: 16/223,251, filed December 18, 2018, the contents of the application, more preferably the examples of the application, are hereby incorporated by
25 reference in their entireties.

Polynucleotides and Vectors

In another general aspect, the application provides a non-naturally occurring nucleic acid molecule encoding an HBV antigen useful for an invention according to embodiments of the application, and vectors comprising the non-naturally occurring nucleic acid. A first or second
30 non-naturally occurring nucleic acid molecule can comprise any polynucleotide sequence encoding an HBV antigen useful for the application, which can be made using methods known in

CA 03141003 2021-12-8

the art in view of the present disclosure. Preferably, a first or second polynucleotide encodes at least one of a truncated HBV core antigen and an HBV polymerase antigen of the application. A polynucleotide can be in the form of RNA or in the form of DNA obtained by recombinant techniques (e.g., cloning) or produced synthetically (e.g., chemical synthesis). The DNA can be 5 single-stranded or double-stranded, or can contain portions of both double-stranded and single-stranded sequence. The DNA can, for example, comprise genomic DNA, cDNA, or combinations thereof. The polynucleotide can also be a DNA/RNA hybrid. The polynucleotides and vectors of the application can be used for recombinant protein production, expression of the protein in host cell, or the production of viral particles. Preferably, a polynucleotide is DNA.

10 In an embodiment of the application, a first non-naturally occurring nucleic acid molecule comprises a first polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% 15 identical to SEQ ID NO: 2, preferably 98%, 99% or 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4. In a particular embodiment of the application, a first non-naturally occurring nucleic acid molecule comprises a first polynucleotide sequence encoding a truncated HBV core antigen consisting the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Examples of polynucleotide sequences of the application encoding a truncated HBV core 20 antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 1 or SEQ ID NO: 3, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, preferably 98%, 99% or 100% identical to SEQ ID 25 NO: 1 or SEQ ID NO: 3. Exemplary non-naturally occurring nucleic acid molecules encoding a truncated HBV core antigen have the polynucleotide sequence of SEQ ID NOs: 1 or 3.

In another embodiment, a first non-naturally occurring nucleic acid molecule further comprises a coding sequence for a signal sequence that is operably linked to the N-terminus of the HBV core antigen sequence. Preferably, the signal sequence has the amino acid sequence of 30 SEQ ID NO: 9 or SEQ ID NO: 15. More preferably, the coding sequence for a signal sequence comprises the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 14.

CA 03141003 2021-12-8

In an embodiment of the application, a second non-naturally occurring nucleic acid molecule comprises a second polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7. In a particular embodiment of the application, a second non-naturally occurring nucleic acid molecule comprises a second polynucleotide sequence encoding an HBV polymerase antigen consisting of the amino acid sequence of SEQ ID NO: 7.

Examples of polynucleotide sequences of the application encoding an HBV Pol antigen comprising the amino acid sequence of at least 90% identical to SEQ ID NO: 7 include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 5 or SEQ ID NO: 6, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6, preferably 98%, 99% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6. Exemplary non-naturally occurring nucleic acid molecules encoding an HBV pol antigen have the polynucleotide sequence of SEQ ID NOs: 5 or 6.

In another embodiment, a second non-naturally occurring nucleic acid molecule further comprises a coding sequence for a signal sequence that is operably linked to the N-terminus of the HBV pol antigen sequence, such as the amino acid sequence of SEQ ID NO: 7. Preferably, the signal sequence has the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15. More preferably, the coding sequence for a signal sequence comprises the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 14.

In another embodiment of the application, a non-naturally occurring nucleic acid molecule encodes an HBV antigen fusion protein comprising a truncated HBV core antigen operably linked to an HBV Pol antigen, or an HBV Pol antigen operably linked to a truncated HBV core antigen. In a particular embodiment, a non-naturally occurring nucleic acid molecule of the application encodes a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 2 or SEQ

CA 03141003 2021-12-8

ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4, more preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO:4; a linker; and an HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 7, preferably 98%, 99% or 100% identical to SEQ ID NO: 7. In a particular embodiment of the application, a non-naturally occurring nucleic acid molecule encodes a fusion protein comprising a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, a linker comprising (AlaGly)n, wherein n is an integer of 2 to 5; and an HBV Pol antigen comprising the amino acid sequence of SEQ ID NO: 7. In a particular embodiment of the application, a non-naturally occurring nucleic acid molecule encodes an HBV antigen fusion protein comprising the amino acid sequence of SEQ ID NO: 16.

Examples of polynucleotide sequences of the application encoding an HBV antigen fusion protein include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 1 or SEQ ID NO: 3, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, preferably 98%, 99% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, operably linked to a linker coding sequence at least 90% identical to SEQ ID NO: 11, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 11, preferably 98%, 99% or 100% identical to SEQ ID NO: 11, which is further operably linked a polynucleotide sequence at least 90% identical to SEQ ID NO: 5 or SEQ ID NO: 6, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6, preferably 98%, 99% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6. In particular embodiments of the application, a non-naturally occurring nucleic acid molecule encoding an HBV antigen fusion protein comprises SEQ ID NO: 1 or SEQ ID NO: 3, operably linked to SEQ ID NO: 11, which is further operably linked to SEQ ID NO: 5 or SEQ ID NO: 6.

In another embodiment, a non-naturally occurring nucleic acid molecule encoding an HBV fusion further comprises a coding sequence for a signal sequence that is operably linked to

CA 03141003 2021-12-8

the N-terminus of the HBV fusion sequence, such as the amino acid sequence of SEQ ID NO: 16. Preferably, the signal sequence has the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15. More preferably, the coding sequence for a signal sequence comprises the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 14. In one embodiment, the encoded
5 fusion protein with the signal sequence comprises the amino acid sequence of SEQ ID NO: 17.

The application also relates to a vector comprising the first and/or second non-naturally occurring nucleic acid molecules. As used herein, a "vector" is a nucleic acid molecule used to carry genetic material into another cell, where it can be replicated and/or expressed. Any vector known to those skilled in the art in view of the present disclosure can be used. Examples of
10 vectors include, but are not limited to, plasmids, viral vectors (bacteriophage, animal viruses, and plant viruses), cosmids, and artificial chromosomes (e.g., YACs). Preferably, a vector is a DNA plasmid. A vector can be a DNA vector or an RNA vector. One of ordinary skill in the art can construct a vector of the application through standard recombinant techniques in view of the present disclosure.

15 A vector of the application can be an expression vector. As used herein, the term "expression vector" refers to any type of genetic construct comprising a nucleic acid coding for an RNA capable of being transcribed. Expression vectors include, but are not limited to, vectors for recombinant protein expression, such as a DNA plasmid or a viral vector, and vectors for delivery of nucleic acid into a subject for expression in a tissue of the subject, such as a DNA
20 plasmid or a viral vector. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.

Vectors of the application can contain a variety of regulatory sequences. As used herein, the term "regulatory sequence" refers to any sequence that allows, contributes or modulates the
25 functional regulation of the nucleic acid molecule, including replication, duplication, transcription, splicing, translation, stability and/or transport of the nucleic acid or one of its derivatives (i.e. mRNA) into the host cell or organism. In the context of the disclosure, this term encompasses promoters, enhancers and other expression control elements (e.g., polyadenylation signals and elements that affect mRNA stability).

30 In some embodiments of the application, a vector is a non-viral vector. Examples of non-viral vectors include, but are not limited to, DNA plasmids, bacterial artificial chromosomes,

CA 03141003 2021-12-8

yeast artificial chromosomes, bacteriophages, etc. Examples of non-viral vectors include, but are not limited to, RNA replicon, mRNA replicon, modified mRNA replicon or self-amplifying mRNA, closed linear deoxyribonucleic acid, e.g. a linear covalently closed DNA such as linear covalently closed double stranded DNA molecule. Preferably, a non-viral vector is a DNA plasmid. A "DNA plasmid", which is used interchangeably with "DNA plasmid vector," "plasmid DNA" or "plasmid DNA vector," refers to a double-stranded and generally circular DNA sequence that is capable of autonomous replication in a suitable host cell. DNA plasmids used for expression of an encoded polynucleotide typically comprise an origin of replication, a multiple cloning site, and a selectable marker, which for example, can be an antibiotic resistance gene. Examples of DNA plasmids suitable that can be used include, but are not limited to, commercially available expression vectors for use in well-known expression systems (including both prokaryotic and eukaryotic systems), such as pSE420 (Invitrogen, San Diego, Calif.), which can be used for production and/or expression of protein in Escherichia coli; pYES2 (Invitrogen, Thermo Fisher Scientific), which can be used for production and/or expression in Saccharomyces cerevisiae strains of yeast; MAXBAC® complete baculovirus expression system (Thermo Fisher Scientific), which can be used for production and/or expression in insect cells; pcDNATM or pcDNA3TM (Life Technologies, Thermo Fisher Scientific), which can be used for high level constitutive protein expression in mammalian cells; and pVAX or pVAX-1 (Life Technologies, Thermo Fisher Scientific), which can be used for high-level transient expression of a protein of interest in most mammalian cells. The backbone of any commercially available DNA plasmid can be modified to optimize protein expression in the host cell, such as to reverse the orientation of certain elements (e.g., origin of replication and/or antibiotic resistance cassette), replace a promoter endogenous to the plasmid (e.g., the promoter in the antibiotic resistance cassette), and/or replace the polynucleotide sequence encoding transcribed proteins (e.g., the coding sequence of the antibiotic resistance gene), by using routine techniques and readily available starting materials. (See e.g., Sambrook et al., Molecular Cloning a Laboratory Manual, Second Ed. Cold Spring Harbor Press (1989)).

Preferably, a DNA plasmid is an expression vector suitable for protein expression in mammalian host cells. Expression vectors suitable for protein expression in mammalian host cells include, but are not limited to, pcDNATM, pcDNA3TM, pVAX, pVAX-1, ADVAX, NTC8454, etc. Preferably, an expression vector is based on pVAX-1, which can be further

modified to optimize protein expression in mammalian cells. pVAX-1 is commonly used plasmid in DNA vaccines, and contains a strong human intermediate early cytomegalovirus (CMV-IE) promoter followed by the bovine growth hormone (bGH)-derived polyadenylation sequence (pA). pVAX-1 further contains a pUC origin of replication and kanamycin resistance gene driven by a small prokaryotic promoter that allows for bacterial plasmid propagation.

A vector of the application can also be a viral vector. In general, viral vectors are genetically engineered viruses carrying modified viral DNA or RNA that has been rendered non-infectious, but still contains viral promoters and transgenes, thus allowing for translation of the transgene through a viral promoter. Because viral vectors are frequently lacking infectious sequences, they require helper viruses or packaging lines for large-scale transfection. Examples of viral vectors that can be used include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, pox virus vectors, enteric virus vectors, Venezuelan Equine Encephalitis virus vectors, Semliki Forest Virus vectors, Tobacco Mosaic Virus vectors, lentiviral vectors, etc. Examples of viral vectors that can be used include, but are not limited to, arenavirus viral vectors, replication-deficient arenavirus viral vectors or replication-competent arenavirus viral vectors, bi-segmented or tri-segmented arenavirus, infectious arenavirus viral vectors, nucleic acids which comprise an arenavirus genomic segment wherein one open reading frame of the genomic segment is deleted or functionally inactivated (and replaced by a nucleic acid encoding an HBV antigen as described herein), arenavirus such as lymphocytic choriomeningitidis virus (LCMV), e.g., clone 13 strain or MP strain, and arenavirus such as Junin virus e.g., Candid #1 strain. The vector can also be a non-viral vector.

Preferably, a viral vector is an adenovirus vector, e.g., a recombinant adenovirus vector. A recombinant adenovirus vector can for instance be derived from a human adenovirus (HAdV, or AdHu), or a simian adenovirus such as chimpanzee or gorilla adenovirus (ChAd, AdCh, or SAdV) or rhesus adenovirus (rhAd). Preferably, an adenovirus vector is a recombinant human adenovirus vector, for instance a recombinant human adenovirus serotype 26, or any one of recombinant human adenovirus serotype 5, 4, 35, 7, 48, etc. In other embodiments, an adenovirus vector is a rhAd vector, e.g. rhAd51, rhAd52 or rhAd53. A recombinant viral vector useful for the application can be prepared using methods known in the art in view of the present disclosure. For example, in view of the degeneracy of the genetic code, several nucleic acid sequences can be designed that encode the same polypeptide. A polynucleotide encoding an

CA 03141003 2021-12-8

HBV antigen of the application can optionally be codon-optimized to ensure proper expression in the host cell (e.g., bacterial or mammalian cells). Codon-optimization is a technology widely applied in the art, and methods for obtaining codon-optimized polynucleotides will be well known to those skilled in the art in view of the present disclosure.

5 A vector of the application, e.g., a DNA plasmid or a viral vector (particularly an adenoviral vector), can comprise any regulatory elements to establish conventional function(s) of the vector, including but not limited to replication and expression of the HBV antigen(s) encoded by the polynucleotide sequence of the vector. Regulatory elements include, but are not limited to, a promoter, an enhancer, a polyadenylation signal, translation stop codon, a ribosome binding 10 element, a transcription terminator, selection markers, origin of replication, etc. A vector can comprise one or more expression cassettes. An "expression cassette" is part of a vector that directs the cellular machinery to make RNA and protein. An expression cassette typically comprises three components: a promoter sequence, an open reading frame, and a 3'-untranslated region (UTR) optionally comprising a polyadenylation signal. An open reading frame (ORF) is 15 a reading frame that contains a coding sequence of a protein of interest (e.g., HBV antigen) from a start codon to a stop codon. Regulatory elements of the expression cassette can be operably linked to a polynucleotide sequence encoding an HBV antigen of interest. As used herein, the term "operably linked" is to be taken in its broadest reasonable context, and refers to a linkage of polynucleotide elements in a functional relationship. A polynucleotide is "operably linked" when 20 it is placed into a functional relationship with another polynucleotide. For instance, a promoter is operably linked to a coding sequence if it affects the transcription of the coding sequence. Any components suitable for use in an expression cassette described herein can be used in any combination and in any order to prepare vectors of the application.

A vector can comprise a promoter sequence, preferably within an expression cassette, to 25 control expression of an HBV antigen of interest. The term "promoter" is used in its conventional sense, and refers to a nucleotide sequence that initiates the transcription of an operably linked nucleotide sequence. A promoter is located on the same strand near the nucleotide sequence it transcribes. Promoters can be a constitutive, inducible, or repressible. Promoters can be naturally occurring or synthetic. A promoter can be derived from sources 30 including viral, bacterial, fungal, plants, insects, and animals. A promoter can be a homologous promoter (i.e., derived from the same genetic source as the vector) or a heterologous promoter

CA 03141003 2021-12-8

(i.e., derived from a different vector or genetic source). For example, if the vector to be employed is a DNA plasmid, the promoter can be endogenous to the plasmid (homologous) or derived from other sources (heterologous). Preferably, the promoter is located upstream of the polynucleotide encoding an HBV antigen within an expression cassette.

5 Examples of promoters that can be used include, but are not limited to, a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter
10 (CMV-IE), Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. A promoter can also be a promoter from a human gene such as human actin, human myosin, human hemoglobin, human muscle creatine, or human metalothionein. A promoter can also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic.

Preferably, a promoter is a strong eukaryotic promoter, preferably a cytomegalovirus
15 immediate early (CMV-IE) promoter. A nucleotide sequence of an exemplary CMV-IE promoter is shown in SEQ ID NO: 18 or SEQ ID NO: 19.

A vector can comprise additional polynucleotide sequences that stabilize the expressed transcript, enhance nuclear export of the RNA transcript, and/or improve transcriptional-translational coupling. Examples of such sequences include polyadenylation signals and
20 enhancer sequences. A polyadenylation signal is typically located downstream of the coding sequence for a protein of interest (e.g., an HBV antigen) within an expression cassette of the vector. Enhancer sequences are regulatory DNA sequences that, when bound by transcription factors, enhance the transcription of an associated gene. An enhancer sequence is preferably located upstream of the polynucleotide sequence encoding an HBV antigen, but downstream of a
25 promoter sequence within an expression cassette of the vector.

Any polyadenylation signal known to those skilled in the art in view of the present disclosure can be used. For example, the polyadenylation signal can be a SV40 polyadenylation signal, LTR polyadenylation signal, bovine growth hormone (bGH) polyadenylation signal, human growth hormone (hGH) polyadenylation signal, or human β-globin polyadenylation
30 signal. Preferably, a polyadenylation signal is a bovine growth hormone (bGH) polyadenylation signal or a SV40 polyadenylation signal. A nucleotide sequence of an exemplary bGH

CA 03141003 2021-12-8

polyadenylation signal is shown in SEQ ID NO: 20. A nucleotide sequence of an exemplary SV40 polyadenylation signal is shown in SEQ ID NO: 13.

Any enhancer sequence known to those skilled in the art in view of the present disclosure can be used. For example, an enhancer sequence can be human actin, human myosin, human hemoglobin, human muscle creatine, or a viral enhancer, such as one from CMV, HA, RSV, or EBV. Examples of particular enhancers include, but are not limited to, Woodchuck HBV Post-transcriptional regulatory element (WPRE), intron/exon sequence derived from human apolipoprotein A1 precursor (ApoAI), untranslated R-U5 domain of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeat (LTR), a splicing enhancer, a synthetic rabbit β-globin intron, or any combination thereof. Preferably, an enhancer sequence is a composite sequence of three consecutive elements of the untranslated R-U5 domain of HTLV-1 LTR, rabbit β-globin intron, and a splicing enhancer, which is referred to herein as "a triple enhancer sequence." A nucleotide sequence of an exemplary triple enhancer sequence is shown in SEQ ID NO: 10. Another exemplary enhancer sequence is an ApoAI gene fragment shown in SEQ ID NO: 12.

A vector can comprise a polynucleotide sequence encoding a signal peptide sequence. Preferably, the polynucleotide sequence encoding the signal peptide sequence is located upstream of the polynucleotide sequence encoding an HBV antigen. Signal peptides typically direct localization of a protein, facilitate secretion of the protein from the cell in which it is produced, and/or improve antigen expression and cross-presentation to antigen-presenting cells. A signal peptide can be present at the N-terminus of an HBV antigen when expressed from the vector, but is cleaved off by signal peptidase, e.g., upon secretion from the cell. An expressed protein in which a signal peptide has been cleaved is often referred to as the "mature protein." Any signal peptide known in the art in view of the present disclosure can be used. For example, a signal peptide can be a cystatin S signal peptide; an immunoglobulin (Ig) secretion signal, such as the Ig heavy chain gamma signal peptide SPIgG or the Ig heavy chain epsilon signal peptide SPIgE.

Preferably, a signal peptide sequence is a cystatin S signal peptide. Exemplary nucleic acid and amino acid sequences of a cystatin S signal peptide are shown in SEQ ID NOs: 8 and 9, respectively. Exemplary nucleic acid and amino acid sequences of an immunoglobulin secretion signal are shown in SEQ ID NOs: 14 and 15, respectively.

CA 03141003 2021-12-8

A vector, such as a DNA plasmid, can also include a bacterial origin of replication and an antibiotic resistance expression cassette for selection and maintenance of the plasmid in bacterial cells, e.g., *E. coli*. Bacterial origins of replication and antibiotic resistance cassettes can be located in a vector in the same orientation as the expression cassette encoding an HBV antigen, or in the opposite (reverse) orientation. An origin of replication (ORI) is a sequence at which replication is initiated, enabling a plasmid to reproduce and survive within cells. Examples of ORIs suitable for use in the application include, but are not limited to ColE1, pMB1, pUC, pSC101, R6K, and 15A, preferably pUC. An exemplary nucleotide sequence of a pUC ORI is shown in SEQ ID NO: 21.

Expression cassettes for selection and maintenance in bacterial cells typically include a promoter sequence operably linked to an antibiotic resistance gene. Preferably, the promoter sequence operably linked to an antibiotic resistance gene differs from the promoter sequence operably linked to a polynucleotide sequence encoding a protein of interest, e.g., HBV antigen. The antibiotic resistance gene can be codon optimized, and the sequence composition of the antibiotic resistance gene is normally adjusted to bacterial, e.g., E. coli, codon usage. Any antibiotic resistance gene known to those skilled in the art in view of the present disclosure can be used, including, but not limited to, kanamycin resistance gene (Kanr), ampicillin resistance gene (Ampr), and tetracycline resistance gene (Tetr), as well as genes conferring resistance to chloramphenicol, bleomycin, spectinomycin, carbenicillin, etc.

Preferably, an antibiotic resistance gene in the antibiotic expression cassette of a vector is a kanamycin resistance gene (Kanr). The sequence of Kanr gene is shown in SEQ ID NO: 22. Preferably, the Kanr gene is codon optimized. An exemplary nucleic acid sequence of a codon optimized Kanr gene is shown in SEQ ID NO: 23. The Kanr can be operably linked to its native promoter, or the Kanr gene can be linked to a heterologous promoter. In a particular embodiment, the Kanr gene is operably linked to the ampicillin resistance gene (Ampr) promoter, known as the bla promoter. An exemplary nucleotide sequence of a bla promoter is shown in SEQ ID NO: 24.

In a particular embodiment of the application, a vector is a DNA plasmid comprising an expression cassette including a polynucleotide encoding at least one of an HBV antigen selected from the group consisting of an HBV pol antigen comprising an amino acid sequence at least 90%, such as 90%, 91%, 92%, 93%, 94%, 95%, 96, 97%, preferably at least 98%, such as at

CA 03141003 2021-12-8

least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, identical to SEQ ID NO: 7, and a truncated HBV core antigen consisting of the amino acid sequence at least 95%, such as 95%, 96, 97%, preferably at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, identical of SEQ ID NO: 2 or SEQ ID NO: 4; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5' end to 3' end, a promoter sequence, preferably a CMV promoter sequence of SEQ ID NO: 18, an enhancer sequence, preferably a triple enhancer sequence of SEQ ID NO: 10, and a polynucleotide sequence encoding a signal peptide sequence, preferably a cystatin S signal peptide having the amino acid sequence of SEQ ID NO: 9; and a downstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising a polyadenylation signal, preferably a bGH polyadenylation signal of SEQ ID NO: 20. Such vector further comprises an antibiotic resistance expression cassette including a polynucleotide encoding an antibiotic resistance gene, preferably a Kan^r gene, more preferably a codon optimized Kan^r gene of at least 90% identical to SEQ ID NO: 23, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 23, preferably 100% identical to SEQ ID NO: 23, operably linked to an Ampr (bla) promoter of SEQ ID NO: 24, upstream of and operably linked to the polynucleotide encoding the antibiotic resistance gene; and an origin of replication, preferably a pUC ori of SEQ ID NO: 21. Preferably, the antibiotic resistance cassette and the origin of replication are present in the plasmid in the reverse orientation relative to the HBV antigen expression cassette.

In another particular embodiment of the application, a vector is a viral vector, preferably an adenoviral vector, more preferably an Ad26 or Ad35 vector, comprising an expression cassette including a polynucleotide encoding at least one of an HBV antigen selected from the group consisting of an HBV pol antigen comprising an amino acid sequence at least 90%, such as 90%, 91%, 92%, 93%, 94%, 95%, 96, 97%, preferably at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%, identical to SEQ ID NO: 7, and a truncated HBV core antigen consisting of the amino acid sequence at least 95%, such as 95%, 96, 97%, preferably at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100%,

CA 03141003 2021-12-8

identical of SEQ ID NO: 2 or SEQ ID NO: 4; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5' end to 3' end, a promoter sequence, preferably a CMV promoter sequence of SEQ ID NO: 19, an enhancer sequence, preferably an ApoAI gene fragment sequence of SEQ ID NO: 12, and a polynucleotide sequence encoding a signal peptide sequence, preferably an immunoglobulin secretion signal having the amino acid sequence of SEQ ID NO: 15; and a downstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising a polyadenylation signal, preferably a SV40 polyadenylation signal of SEQ ID NO: 13.

In an embodiment of the application, a vector, such as a plasmid DNA vector or a viral vector (preferably an adenoviral vector, more preferably an Ad26 or Ad35 vector), encodes an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 7. Preferably, the vector comprises a coding sequence for the HBV Pol antigen that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: 5 or 6, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 5 or 6, preferably 100% identical to SEQ ID NO: 5 or 6.

In an embodiment of the application, a vector, such as a plasmid DNA vector or a viral vector (preferably an adenoviral vector, more preferably an Ad26 or Ad35 vector), encodes a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. Preferably, the vector comprises a coding sequence for the truncated HBV core antigen that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, preferably 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3.

In yet another embodiment of the application, a vector, such as a plasmid DNA vector or a viral vector (preferably an adenoviral vector, more preferably an Ad26 or Ad35 vector), encodes a fusion protein comprising an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 7 and a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3. Preferably, the vector comprises a coding sequence for the fusion, which contains a coding sequence for the truncated HBV core antigen at least 90% identical to SEQ ID NO: 1 or SEQ ID NO: 3, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%,

CA 03141003 2021-12-8

96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, preferably 98%, 99% or 100% identical to SEQ ID NO: 1 or SEQ ID NO: 3, more preferably SEQ ID NO: 1 or SEQ ID NO: 3, operably linked to a coding sequence for the HBV Pol antigen at least 90% identical to SEQ ID NO: 5 or SEQ ID NO: 6, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6, preferably 98%, 99% or 100% identical to SEQ ID NO: 5 or SEQ ID NO: 6, more preferably SEQ ID NO: 5 or SEQ ID NO: 6. Preferably, the coding sequence for the truncated HBV core antigen is operably linked to the coding sequence for the HBV Pol antigen via a coding sequence for a linker at least 90% identical to SEQ ID NO: 11, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 11, preferably 98%, 99% or 100% identical to SEQ ID NO: 11. In particular embodiments of the application, a vector comprises a coding sequence for the fusion having SEQ ID NO: 1 or SEQ ID NO: 3 operably linked to SEQ ID NO: 11, which is further operably linked to SEQ ID NO: 5 or SEQ ID NO: 6.

The polynucleotides and expression vectors encoding the HBV antigens of the application can be made by any method known in the art in view of the present disclosure. For example, a polynucleotide encoding an HBV antigen can be introduced or "cloned" into an expression vector using standard molecular biology techniques, e.g., polymerase chain reaction (PCR), etc., which are well known to those skilled in the art.

Cells, Polypeptides and Antibodies

The application also provides cells, preferably isolated cells, comprising any of the polynucleotides and vectors described herein. The cells can, for instance, be used for recombinant protein production, or for the production of viral particles.

Embodiments of the application thus also relate to a method of making an HBV antigen of the application. The method comprises transfecting a host cell with an expression vector comprising a polynucleotide encoding an HBV antigen of the application operably linked to a promoter, growing the transfected cell under conditions suitable for expression of the HBV antigen, and optionally purifying or isolating the HBV antigen expressed in the cell. The HBV antigen can be isolated or collected from the cell by any method known in the art including

CA 03141003 2021-12-8

affinity chromatography, size exclusion chromatography, etc. Techniques used for recombinant protein expression will be well known to one of ordinary skill in the art in view of the present disclosure. The expressed HBV antigens can also be studied without purifying or isolating the expressed protein, e.g., by analyzing the supernatant of cells transfected with an expression vector encoding the HBV antigen and grown under conditions suitable for expression of the HBV antigen.

Thus, also provided are non-naturally occurring or recombinant polypeptides comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 7. As described above and below, isolated nucleic acid molecules encoding these sequences, vectors comprising these sequences operably linked to a promoter, and compositions comprising the polypeptide, polynucleotide, or vector are also contemplated by the application.

In an embodiment of the application, a recombinant polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 2. Preferably, a non-naturally occurring or recombinant polypeptide consists of SEQ ID NO: 2.

In another embodiment of the application, a non-naturally occurring or recombinant polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 4, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 4. Preferably, a non-naturally occurring or recombinant polypeptide comprises SEQ ID NO: 4.

In another embodiment of the application, a non-naturally occurring or recombinant polypeptide comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 7, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 7. Preferably, a non-naturally occurring or recombinant polypeptide consists of SEQ ID NO: 7.

Also provided are antibodies or antigen binding fragments thereof that specifically bind to a non-naturally occurring polypeptide of the application. In an embodiment of the application,

CA 03141003 2021-12-8

an antibody specific to a non-naturally HBV antigen of the application does not bind specifically to another HBV antigen. For example, an antibody of the application that binds specifically to an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 7 will not bind specifically to an HBV Pol antigen not having the amino acid sequence of SEQ ID NO: 7.

5 As used herein, the term "antibody" includes polyclonal, monoclonal, chimeric, humanized, Fv, Fab and F(ab')2; bifunctional hybrid (e.g., Lanzavecchia et al., Eur. J. Immunol. 17:105, 1987), single-chain (Huston et al., Proc. Natl. Acad. Sci. USA 85:5879, 1988; Bird et al., Science 242:423, 1988); and antibodies with altered constant regions (e.g., U.S. Pat. No. 5,624,821).

10 As used herein, an antibody that "specifically binds to" an antigen refers to an antibody that binds to the antigen with a KD of 1×10^{-7} M or less. Preferably, an antibody that "specifically binds to" an antigen binds to the antigen with a KD of 1×10^{-8} M or less, more preferably 5×10^{-9} M or less, 1×10^{-9} M or less, 5×10^{-10} M or less, or 1×10^{-10} M or less. The term "KD" refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e.,
15 Kd/Ka) and is expressed as a molar concentration (M). KD values for antibodies can be determined using methods in the art in view of the present disclosure. For example, the KD of an antibody can be determined by using surface plasmon resonance, such as by using a biosensor system, e.g., a Biacore® system, or by using bio-layer interferometry technology, such as a Octet RED96 system.

20 The smaller the value of the KD of an antibody, the higher affinity that the antibody binds to a target antigen.

PD-L1 Inhibitors

Programmed death-ligand 1 (PD-L1) is a 40 kDa immune checkpoint protein encoded in humans by the *CD274* gene. Upon binding to its receptor PD-1, which is expressed on activated
25 B cells, T cells, and myeloid cells, PD-L1 initiates signaling pathways that lead to downregulation of T cell proliferation and activation, facilitating tumor cell escape from T cell-mediated immune surveillance, thereby contributing to cancer severity and progression. PD-L1 expression has been shown on a wide variety of solid tumors (e.g., breast, lung, colon, ovarian, melanoma, bladder, liver, salivary, stomach, gliomas, thyroid, thymic epithelial, head, and neck
30 (Brown J A et al., 2003. J. Immunol. 170:1257-66; Dong H et al. 2002. Nat. Med. 8:793-800; Hamanishi J, et al. 2007. Proc. Natl. Acad. Sci. USA 104:3360-65; Strome S E et al. 2003.

Cancer Res. 63:6501-5; Inman B A et al. 2007. Cancer 109:1499-505; Konishi J et al. 2004. Clin. Cancer Res. 10:5094-100; Nakanishi J et al. 2007. Cancer Immunol. Immunother. 56:1173-82)), and the protein has arisen as an attractive target for the development of anti-cancer therapeutics. PD-L1 expression is further involved in the evasion of immune responses involved in infectious diseases (e.g., chronic viral infections including HBV and HIV). As such, PD-L1 also serves as a therapeutic target for the treatment of a variety of infectious diseases. Therapeutic efficacy of PD-L1 antagonists (and of PD-1 antagonists) has been validated in clinical trials. The PD-L1 inhibitors described herein can be useful for treating or preventing, in particular treating, infectious diseases, such as viral, bacterial, fungal, and parasitic infections, particularly viral infections. In some embodiments, the PD-L1 inhibitors described herein can be used in the treatment of chronic infection, such as chronic viral infection, e.g., chronic HBV infection.

The PD-L1 inhibitors of the application can also be combined with other agents that stimulate or enhance the immune response, such as vaccines. For example, the PD-L1 inhibitors described herein can be used in compositions, therapeutic combinations, and kits comprising one or more HBV antigens, polynucleotides, and/or vectors encoding one or more HBV antigens according to the application (e.g., HBV vaccines), as described in more detail below.

According to embodiments of the application, a PD-L1 inhibitor is a compound of formula (I), described in European Patent Application EP19179072.4, filed June 7, 2019, the contents of which are hereby incorporated by reference in their entirety:

(I)

In formula (I), R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$,

CA 03141003 2021-12-8

$NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-membered heteroaryl), and a ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H, halogen, C_{1-4}alkyl and C_{1-4}alkyl substituted with one or more F;

5 R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one or more substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, C_{3-6}heterocycle, aryl and heteroaryl;

wherein C_{3-6}heterocycle is optionally substituted with one or more substituent selected from oxo, OH and CO_2H;

10 with the proviso that R^8 and R^9 are not both H;

or wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle optionally substituted with one or more substituents selected from C_{1-6}alkyl, oxo, OH and CO_2H;

R^{10} is selected from H, CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$,

15 $C(=O)NR^xR^y$, SO_2-C_{1-6}alkyl, aryl and heteroaryl;

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl;

20 X is N or CR^{12};

R^{12} is selected from H, F, Cl, CN, $C(=O)NR^xR^y$, aryl and heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$,

25 $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl; and

R^x and R^y are independently selected from H and C_{1-6}alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

For the purposes of this disclosure, the terms "compound(s) of the application" or

30 "compound(s) according to the application" is meant to include the compounds of Formula (I),

CA 03141003 2021-12-8

which further include, without limitation, stereoisomers, tautomers, pharmaceutically acceptable salts, prodrugs, solvates, hydrates, and polymorphs thereof.

The term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 12 carbon atoms in the chain. Examples of alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, "/"), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. The term C_{1-4}alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain. The term C_{1-6}alkyl as used here refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain.

The terms "alkoxy," "alkylamino," and "alkylthio" are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an O atom, an amino group, or a S atom, respectively.

The term "heteroalkyl" refers to a stable straight or branched chain, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N and S. The heteroatoms may be placed at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.

The term "haloalkyl" is used in its conventional sense, and refers to an alkyl group, as defined herein, substituted with one or more halo substituents.

The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle. Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:

▷, □, ⬠, ⬡, ◯ and ◯.

The terms "heterocycle" and "heterocycloalkyl" refer to saturated or partially saturated monocyclic, fused polycyclic, or spiro polycyclic ring systems having 3 to 12 ring members and which contain carbon atoms and from 1 to 5 heteroatoms independently selected from the group consisting of N, O, and S. The terms "heterocycle" and "heterocycloalkyl" include cyclic esters

CA 03141003 2021-12-8

(e.g., lactones) and cyclic amides (e.g., lactams). Examples of heterocycle and heterocycloalkyl groups include, but are not limited to, epoxidyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl (i.e., oxanyl), pyranyl, dioxanyl, aziridinyl, azetidinyl, pyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, oxazolidinyl, thiazolidinyl, piperidinyl, morpholinyl, piperazinyl, thiomorpholinyl, and benzo-1,4-dioxane. Unless otherwise noted, the heterocycle or heterocycloalkyl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

A monocyclic, bicyclic or tricyclic aromatic carbocycle represents an aromatic ring system consisting of 1, 2 or 3 rings, said ring system being composed of only carbon atoms; the term aromatic is well known to a person skilled in the art and designates cyclically conjugated systems of 4n + 2 electrons, that is with 6, 10, 14 etc. π-electrons (rule of Hückel).

Particular examples of monocyclic, bicyclic or tricyclic aromatic carbocycles are phenyl, naphthyl, anthracenyl.

The term "phenyl" represents the following moiety:

The term "aryl," unless otherwise stated," refers to a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. Examples of aryl groups include phenyl, naphthyl, anthracenyl.

The term "heteroaryl" refers to a monocyclic or bicyclic aryl ring system having 5 to 10 ring members and which contains carbon atoms and from 1 to 5 heteroatoms independently selected from the group consisting of N, O, and S. Included within the term heteroaryl are aromatic rings of 5 or 6 members wherein the ring consists of carbon atoms and has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen, and sulfur. In the case of 5-membered rings, the heteroaryl ring preferably contains one member of nitrogen, oxygen or sulfur and, in addition, up to 3 additional nitrogens. In the case of 6-membered rings, the heteroaryl ring preferably contains from 1 to 3 nitrogen atoms. For the case wherein the 6-membered ring has 3 nitrogens, at most 2 nitrogen atoms are adjacent. Examples of heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl,

CA 03141003 2021-12-8

benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl and quinazolinyl. Unless otherwise noted, the heteroaryl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.

Those skilled in the art will recognize that the species of heteroaryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.

The term “cyano” refers to the group -CN.

The terms “halo” or “halogen” represent chloro, fluoro, bromo, or iodo.

The term “substituted” means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents.

The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.

The terms “para”, “meta”, and “ortho” have the meanings as understood in the art. Thus, for example, a fully substituted phenyl group has substituents at both “ortho”(*o*) positions adjacent to the point of attachment of the phenyl ring, both “meta” (*m*) positions, and the one “para” (*p*) position across from the point of attachment. To further clarify the position of substituents on the phenyl ring, the 2 different ortho positions will be designated as ortho and ortho’ and the 2 different meta positions as meta and meta’ as illustrated below.

When referring to substituents on a pyridyl group, the terms “para”, “meta”, and “ortho” refer to the placement of a substituent relative to the point of attachment of the pyridyl ring. For example, the structure below is described as 3-pyridyl with the X^1 substituent in the ortho position, the X^2 substituent in the meta position, and X^3 substituent in the para position:

X^1 X^2 2 N 3 X^3 .

When any variable occurs more than one time in any constituent, each definition is independent.

5 When any variable occurs more than one time in any formula (e.g. Formula (I)), each definition is independent.

As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. *R*, *S*) around one or more atoms, contemplates each possible stereoisomer, or
10 mixture of two or more stereoisomers All stereoisomers of the compounds described herein either as a pure stereoisomer or as a mixture of two or more stereoisomers are included within the scope of the application.

The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" are used interchangeably.

15 Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
Atropisomers (or atropoisomers) are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large steric hindrance.
Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not
20 related as mirror images. If a compound contains a double bond, the substituents may be in the *E* or the *Z* configuration.

Substituents on bivalent cyclic saturated or partially saturated radicals can have either the cis- or trans-configuration; for example, if a compound contains a disubstituted cycloalkyl group, the substituents can be in the cis or trans configuration.

25 The application includes enantiomers, atropisomers, diastereomers, racemates, *E* isomers, *Z* isomers, cis isomers, trans isomers and mixtures thereof of compounds of formula (I), whenever chemically possible. The meaning of all such terms, i.e. enantiomers, atropisomers, diastereomers, racemates, *E* isomers, *Z* isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.

CA 03141003 2021-12-8

The absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration at an asymmetric atom is specified by either *R* or *S*. Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For instance, resolved enantiomers whose absolute
5 configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.

When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably
10 less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is for instance specified as (*R*), this means that the compound is substantially free of the (*S*) isomer; when a compound of Formula (I) is for instance specified as *E*, this means that the compound is substantially free of the *Z* isomer; when a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.

15 The stereochemical configuration for centers in some compounds may be designated "*R*" or "*S*" when the mixture(s) was separated; for some compounds, the stereochemical configuration at indicated centers has been designated as "*R**" or "*S**" when the absolute stereochemistry is undetermined (even if the bonds are drawn stereo specifically) although the compound itself has been isolated as a single stereoisomer and is enantiomerically pure.

20 Some of the compounds according to Formula (I) described herein can also exist in their tautomeric form. Such forms in so far as they may exist, although not explicitly indicated in the above Formula (I) are intended to be included within the scope of the application. It follows that a single compound may exist in both stereoisomeric and tautomeric form.

Pharmaceutically acceptable salts include acid addition salts and base addition salts.
25 Such salts can be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate base or acid, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. *in vacuo*, by freeze-drying or by filtration). Salts can also be prepared by exchanging a counter-ion of a compound of the application in the form of a salt with
30 another counter-ion, for example using a suitable ion exchange resin.

The pharmaceutically acceptable addition salts as mentioned herein comprise the

CA 03141003 2021-12-8

therapeutically active non-toxic acid and base salt forms which the compounds of formula (I), N-oxides and solvates thereof, are capable of forming. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

Additionally, any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly. Certain compounds of Formula (I), or pharmaceutically acceptable salts of compounds of Formula (I), may be obtained as solvates. Solvates include those formed from the interaction or complexation of compounds of the disclosure with one or more solvents, either in solution or as a solid or crystalline form. In some embodiments, the solvent is water and the solvates are hydrates. In addition, certain crystalline forms of compounds of Formula (I), or pharmaceutically acceptable salts of compounds of Formula (I) may be obtained as co-crystals. In certain embodiments of the disclosure, compounds of Formula (I) were obtained in a crystalline form. In other embodiments, crystalline forms of compounds of Formula (I) were cubic in nature. In other embodiments, pharmaceutically acceptable salts of compounds of Formula (I) were obtained in a crystalline form. In still other embodiments, compounds of Formula (I) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form. In other embodiments, compounds of Formula (I) convert in solution between one or more crystalline forms and/or polymorphic forms.

The compounds of formula (I) and solvates thereof containing an acidic proton can also be converted into their non-toxic metal or amine salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, cesium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine,

CA 03141003 2021-12-8

triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

5 The compounds of formula (I) and solvates thereof containing an acidic proton can also be converted into their non-toxic metal or amine salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, cesium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic 10 and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, 15 arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

The term "solvate" comprises the solvent addition forms as well as the salts thereof, which the compounds of Formula (I) are able to form. Examples of such solvent addition forms are e.g. hydrates, alcoholates and the like.

20 The term "enantiomerically pure" as used herein means that the product contains at least 80% by weight of one enantiomer and 20% by weight or less of the other enantiomer. Preferably the product contains at least 90% by weight of one enantiomer and 10% by weight or less of the other enantiomer. In the most preferred embodiment the term "enantiomerically pure" means that the composition contains at least 99% by weight of one enantiomer and 1% or less of the other 25 enantiomer.

Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as R-COOH, encompasses reference to any one of, for example, R-$COOH_{(s)}$, R- 30 $COOH_{(sol)}$, and R-$COO^{-}_{(sol)}$. In this example, R-$COOH_{(s)}$ refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; R-

CA 03141003 2021-12-8

$COOH_{(sol)}$ refers to the undissociated form of the compound in a solvent; and $R\text{-}COO^{-}_{(sol)}$ refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields $R\text{-}COO^{-}$ upon dissociation in the medium
5 being considered. In another example, an expression such as "exposing an entity to compound of formula R-COOH" refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In still another example, an expression such as "reacting an entity with a compound of formula R-COOH" refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that
10 exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment, it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as $R\text{-}COOH_{(aq)}$ and/or $R\text{-}COO^{-}_{(aq)}$, where the subscript "(aq)"
15 stands for "aqueous" according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that
20 interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.
25 In another example, a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification
30 CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound

that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term "inner salts". Other sources refer to these compounds as "dipolar ions", although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula H_2NCH_2COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion $^{+}H_3NCH_2COO^{-}$. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well established meanings of these terms are within the scope of this disclosure, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this disclosure are given explicitly herein. They are, however, part of the embodiments of this disclosure. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.

The disclosure also embraces isotopically-labeled compounds of the application which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).

All isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the application, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C , ^{13}N, ^{15}O, ^{17}O, ^{18}O, ^{32}P, ^{33}P, ^{35}S, ^{18}F, ^{36}Cl, ^{122}I, ^{123}I, ^{125}I, ^{131}I, ^{75}Br, ^{76}Br, ^{77}Br and ^{82}Br. Preferably, the radioactive isotope is selected from the group of ^{2}H, ^{3}H, ^{11}C and ^{18}F. More preferably, the radioactive isotope is ^{2}H. In particular, deuterated compounds are intended to be included within the scope of the application.

Certain isotopically-labeled compounds of the application (e.g., those labeled with ^{3}H and ^{14}C) may be useful for example in substrate tissue distribution assays. Tritiated (^{3}H) and carbon-14 (^{14}C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., ^{2}H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased *in vivo* half-life or reduced dosage

CA 03141003 2021-12-8

requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as ^{15}O, ^{13}N, ^{11}C and ^{18}F are useful for positron emission tomography (PET) studies. PET imaging in cancer finds utility in helping locate and identify tumours, stage the disease and determine suitable treatment. Human cancer cells overexpress many receptors or proteins that
5 are potential disease-specific molecular targets. Radiolabelled tracers that bind with high affinity and specificity to such receptors or proteins on tumour cells have great potential for diagnostic imaging and targeted radionuclide therapy (Charron, Carlie L. et al. Tetrahedron Lett. 2016, 57(37), 4119-4127). Additionally, target-specific PET radiotracers can be used as biomarkers to examine and evaluate pathology, by for example, measuring target expression and
10 treatment response (Austin R. et al. Cancer Letters (2016), doi: 10.1016/j.canlet.2016.05.008).

In some embodiments, provided is a compound of formula (I), and the tautomers and the stereoisomeric forms thereof, wherein R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, and a ring.

15 In an embodiment, provided is a compound of formula (I) wherein R^1 is 6 to 10-membered aryl, 5 to 10-membered heteroaryl, or 5 to 10-membered heterocycle optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-membered heteroaryl), 6 to 10-
20 membered aryl, 5 to 10-membered heteroaryl, 5 to 10-membered heterocycle, and 5-10-membered cycloalkyl.

In an embodiment, provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally substituted monocyclic or bicyclic ring. In another embodiment, provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally substituted bicyclic ring. In yet another embodiment,
25 provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally substituted bicyclic ring wherein the two rings of the bicycle are fused together or covalently bound to one another. In still another embodiment, provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally substituted bicyclic ring wherein the two rings of the bicycle are fused together.

In an embodiment, provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally
30 substituted monocyclic or bicyclic aryl, heteroaryl, or heterocycle group. In another embodiment, provided is a compound of formula (I) wherein $\mathbf{R^1}$ is an optionally substituted bicyclic aryl,

CA 03141003 2021-12-8

heteroaryl, or heterocycle group. In yet another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted bicyclic aryl, heteroaryl, or heterocycle group wherein the two rings of the bicycle are fused together or covalently bound to one another. In still another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted
5 bicyclic aryl, heteroaryl, or heterocycle group wherein the two rings of the bicycle are fused together.

In an embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted ring wherein the ring optionally comprises one or more heteroatoms. In another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted ring
10 wherein the ring optionally comprises one or more heteroatoms each independently selected from O, S, and N. In yet another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted ring wherein the ring optionally comprises one or more oxygen atoms.

In an embodiment, provided is a compound of formula (I) wherein R^1 is an optionally
15 substituted ring that is saturated. In another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted ring that is unsaturated. In yet another embodiment, provided is a compound of formula (I) wherein R^1 is an optionally substituted ring that is a combination of saturated and unsaturated.

In some embodiments, provided is a compound of formula (I) wherein R^1 is selected
20 from the following rings:

(g-1) (g-2) (g-3)

In some embodiments, provided is a compound of formula (I) wherein R^1 is Formula (g-1):

(g-1)

25 In some embodiments, provided is a compound of formula (I) wherein R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H and C_{1-4}alkyl.

CA 03141003 2021-12-8

In some embodiments, provided is a compound of formula (I) wherein R^2, R^3, R^4, R^5, R^7 and R^{11} are independently selected from H and C_{1-4}alkyl.

In some embodiments, provided is a compound of formula (I) wherein R^6 is C_{1-4}alkyl or Cl.

5 In some embodiments, provided is a compound of formula (I) wherein R^6 is Cl, and R^2, R^3, R^4, R^5, R^7 and R^{11} are H.

In some embodiments, provided is a compound of formula (I) wherein R^8 is H and R^9 is C_{1-6}alkyl substituted with OH and CO_2H.

In some embodiments, provided is a compound of formula (I) wherein R^8 and R^9 are
10 independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one, two, or three substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, aryl and heteroaryl.

In some embodiments, provided is a compound of formula (I) wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle substituted with OH and CO_2H. In some
15 embodiments, the C_{3-6}heterocycle is pyrrolidine.

In some embodiments, provided is a compound of formula (I) wherein R^{10} is selected from H and CN.

In some embodiments, provided is a compound of formula (I) wherein R^{12} is selected from H, Cl, and CN.

20 In some embodiments, provided is a compound of formula (I) wherein R^{10} is CN, and X is N.

In some embodiments, provided is a compound of formula (I) wherein R^{10} is H, and X is N.

In some embodiments, provided are compounds 7, 8, 9, 10, 11, 12, 101, 103, 202, 203,
25 and 204, and the stereoisomers or tautomeric forms thereof, or a pharmaceutically acceptable salt thereof:

CA 03141003 2021-12-8

compound 7	compound 8
compound 9	compound 10
compound 11	compound 12
compound 101	compound 103

compound 202	compound 203
compound 204	

In some embodiments, provided are compounds 205, 207, and 209, and the stereoisomers or tautomeric forms thereof, or a pharmaceutically acceptable salt thereof:

compound 205	compound 207

CA 03141003 2021-12-8

compound 209	

In particular embodiments provided is a compound selected from the group consisting of any of the exemplified compounds, tautomers and stereoisomeric forms thereof, and any pharmaceutically acceptable salts, prodrugs, hydrates, polymorphs, and solvates thereof.

5 All possible combinations of the above indicated embodiments are considered to be embraced within the scope of the invention.

Compounds of formula (I) can be prepared according to the general preparation methods and preparation of some typical examples of the compounds of formula (I) as described below.

10 The compounds of formula (I) are generally prepared from starting materials which are either commercially available or prepared by standard synthetic processes commonly used by those skilled in the art of organic chemistry. The following schemes are only meant to provide examples and are not limiting.

Alternatively, compounds of the application can also be prepared by analogous reaction

15 protocols as described in the general schemes below and the specific examples, combined with standard synthetic processes commonly used by those skilled in the art.

The skilled person will realize that in the reactions described in the Schemes, although this is not always explicitly shown, it may be necessary to protect reactive functional groups (for example hydroxy, amino, or carboxy groups) where these are desired in the final product, to

20 avoid their unwanted participation in the reactions. In general, conventional protecting groups can be used in accordance with standard practice. The protecting groups can be removed at a convenient subsequent stage using methods known from the art.

CA 03141003 2021-12-8

The skilled person will realize that in the reactions described in the Schemes, it may be advisable or necessary to perform the reaction under an inert atmosphere, such as for example under N_2-gas atmosphere.

It will be apparent for the skilled person that it may be necessary to cool the reaction
5 mixture before reaction work-up (which refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).

The skilled person will realize that heating the reaction mixture under stirring may enhance the reaction outcome. In some reactions microwave heating may be used instead of
10 conventional heating to shorten the overall reaction time.

The skilled person will realize that intermediates and final compounds shown in the Schemes below may be further functionalized according to methods well-known by the person skilled in the art. The intermediates and compounds described herein can be isolated in free form or as a salt, or a solvate thereof. The intermediates and compounds described herein may
15 be synthesized in the form of mixtures of tautomers and stereoisomeric forms that can be separated from one another following art-known resolution procedures.

Scheme 1

In general, compounds of Formula (I) wherein all variables are defined according to the scope of the application, can be prepared by reacting a compound of Formula (II),

20 (II) ,

with an amine of Formula (III),

(III) ,

in the presence of sodium cyanoborohydride, wherein R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11} and X have been defined herein.

CA 03141003 2021-12-8

It will be appreciated that where appropriate functional groups exist, compounds of various formulae or any intermediates used in their preparation may be further derivatised by one or more standard synthetic methods employing condensation, substitution, oxidation, reduction, or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, sulfonylation, halogenation, nitration, formylation and coupling procedures.

The compounds of formula (I) can be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) containing a basic nitrogen atom can be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Pure stereochemically isomeric forms canalso be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

Additional disclosure on PD-L1 inhibitors that can be used in the invention are described in European Patent Application EP19179072.4, filed June 7, 2019, the contents of which are hereby incorporated by reference in their entirety.

Compositions, Therapeutic Combinations, and Vaccines

The application also relates to compositions, therapeutic combinations, more particularly kits, and vaccines comprising one or more HBV antigens, polynucleotides, and/or vectors encoding one or more HBV antigens according to the application. Any of the HBV antigens, polynucleotides (including RNA and DNA), and/or vectors of the application described herein can be used in the compositions, therapeutic combinations or kits, and vaccines of the application.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, or an HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, a vector comprising the isolated or non-

CA 03141003 2021-12-8

naturally occurring nucleic acid molecule, and/or an isolated or non-naturally occurring polypeptide encoded by the isolated or non-naturally occurring nucleic acid molecule.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising a polynucleotide sequence encoding an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising a polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4; and an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising a polynucleotide sequence encoding an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7. The coding sequences for the truncated HBV core antigen and the HBV Pol antigen can be present in the same isolated or non-naturally occurring nucleic acid molecule (DNA or RNA), or in two different isolated or non-naturally occurring nucleic acid molecules (DNA or RNA).

In an embodiment of the application, a composition comprises a vector, preferably a DNA plasmid or a viral vector (such as an adenoviral vector) comprising a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4.

In an embodiment of the application, a composition comprises a vector, preferably a DNA plasmid or a viral vector (such as an adenoviral vector), comprising a polynucleotide encoding an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7.

In an embodiment of the application, a composition comprises a vector, preferably a DNA plasmid or a viral vector (such as an adenoviral vector), comprising a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to

CA 03141003 2021-12-8

SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4; and a vector, preferably a DNA plasmid or a viral vector (such as an adenoviral vector), comprising a polynucleotide encoding an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7. The vector comprising the coding sequence for the truncated HBV core antigen and the vector comprising the coding sequence for the HBV Pol antigen can be the same vector, or two different vectors.

In an embodiment of the application, a composition comprises a vector, preferably a DNA plasmid or a viral vector (such as an adenoviral vector), comprising a polynucleotide encoding a fusion protein comprising a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4, operably linked to an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7, or vice versa. Preferably, the fusion protein further comprises a linker that operably links the truncated HBV core antigen to the HBV Pol antigen, or vice versa. Preferably, the linker has the amino acid sequence of (AlaGly)n, wherein n is an integer of 2 to 5.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4; and an isolated or non-naturally occurring HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7.

In an embodiment of the application, a composition comprises an isolated or non-naturally occurring fusion protein comprising a truncated HBV core antigen consisting of an amino acid

CA 03141003 2021-12-8

sequence that is at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 14, preferably 100% identical to SEQ ID NO: 2 or SEQ ID NO: 4, operably linked to an HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, preferably 100% identical to SEQ ID NO: 7, or vice versa. Preferably, the fusion protein further comprises a linker that
5 operably links the truncated HBV core antigen to the HBV Pol antigen, or vice versa. Preferably, the linker has the amino acid sequence of (AlaGly)n, wherein n is an integer of 2 to 5.

The application also relates to a therapeutic combination or a kit comprising polynucleotides expressing a truncated HBV core antigen and an HBV pol antigen according to embodiments of the application. Any polynucleotides and/or vectors encoding HBV core and pol
10 antigens of the application described herein can be used in the therapeutic combinations or kits of the application.

According to embodiments of the application, a therapeutic combination or kit for use in treating an HBV infection in a subject in need thereof, comprises:

i) at least one of:

15 a) a truncated HBV core antigen consisting of an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and

b) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding the truncated HBV core antigen

c) an HBV polymerase antigen having an amino acid sequence that is at least 90%
20 identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity, and

d) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding the HBV polymerase antigen; and

ii) a compound of formula (I):

25

CA 03141003 2021-12-8

(I)

In formula (I), R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-
5 membered heteroaryl), and a ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H, halogen, C_{1-4}alkyl and C_{1-4}alkyl substituted with one or more F;

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one or more substituents selected
10 from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, C_{3-6}heterocycle, aryl and heteroaryl;

wherein C_{3-6}heterocycle is optionally substituted with one or more substituent selected from oxo, OH and CO_2H;

with the proviso that R^8 and R^9 are not both H;

or wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle optionally
15 substituted with one or more substituents selected from C_{1-6}alkyl, oxo, OH and CO_2H;

R^{10} is selected from H, CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-$C(O)NH_2$, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-$C(O)N(C_{1-6}alkyl)_2$, $C(=O)NR^xR^y$, SO_2-C_{1-6}alkyl, aryl and heteroaryl;

wherein aryl and heteroaryl are optionally substituted with one or more substituents
20 selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-$C(O)NH_2$, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-$C(O)N(C_{1-6}alkyl)_2$, $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl;

X is N or CR^{12};

R^{12} is selected from H, F, Cl, CN, $C(=O)NR^xR^y$, aryl and heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, C(=O)NR^xR^y and SO_2-C_{1-6}alkyl; and

5 R^x and R^y are independently selected from H and C_{1-6}alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

Any of the embodiments of the compounds of formula (I) described herein can be used in a therapeutic combination of the application.

10 In a particular embodiment of the application, a therapeutic combination or kit comprises: i) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 95% identical to SEQ ID NO: 2; ii) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having an amino acid

15 sequence that is at least 90% identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; and iii) a compound of formula (I):

(I)

or a tautomer, stereoisomer, or pharmaceutically acceptable form thereof, wherein:

20 R^1 is an optionally substituted monocyclic or bicyclic ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H and C_{1-4}alkyl;

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one, two, or three substituents selected from C_{1-4}alkyl, OH, OCH_3, -CO_2H, -CO_2C_{1-4}alkyl, aryl and heteroaryl;

25 R^{10} is selected from H and CN;

CA 03141003 2021-12-8

R^{12} is selected from H, Cl, and CN; and

X is N.

According to embodiments of the application, the polynucleotides in a vaccine combination or kit can be linked or separate, such that the HBV antigens expressed from such polynucleotides are fused together or produced as separate proteins, whether expressed from the same or different polynucleotides. In an embodiment, the first and second polynucleotides are present in separate vectors, e.g., DNA plasmids or viral vectors, used in combination either in the same or separate compositions, such that the expressed proteins are also separate proteins, but used in combination. In another embodiment, the HBV antigens encoded by the first and second polynucleotides can be expressed from the same vector, such that an HBV core-pol fusion antigen is produced. Optionally, the core and pol antigens can be joined or fused together by a short linker. Alternatively, the HBV antigens encoded by the first and second polynucleotides can be expressed independently from a single vector using a using a ribosomal slippage site (also known as cis-hydrolase site) between the core and pol antigen coding sequences. This strategy results in a bicistronic expression vector in which individual core and pol antigens are produced from a single mRNA transcript. The core and pol antigens produced from such a bicistronic expression vector can have additional N or C-terminal residues, depending upon the ordering of the coding sequences on the mRNA transcript. Examples of ribosomal slippage sites that can be used for this purpose include, but are not limited to, the FA2 slippage site from foot-and-mouth disease virus (FMDV). Another possibility is that the HBV antigens encoded by the first and second polynucleotides can be expressed independently from two separate vectors, one encoding the HBV core antigen and one encoding the HBV pol antigen.

In a preferred embodiment, the first and second polynucleotides are present in separate vectors, e.g., DNA plasmids or viral vectors. Preferably, the separate vectors are present in the same composition.

According to preferred embodiments of the application, a therapeutic combination or kit comprises a first polynucleotide present in a first vector, a second polynucleotide present in a second vector. The first and second vectors can be the same or different. Preferably the vectors are DNA plasmids.

CA 03141003 2021-12-8

In a particular embodiment of the application, the first vector is a first DNA plasmid, the second vector is a second DNA plasmid. Each of the first and second DNA plasmids comprises an origin of replication, preferably pUC ORI of SEQ ID NO: 21, and an antibiotic resistance cassette, preferably comprising a codon optimized Kanr gene having a polynucleotide sequence that is at least 90% identical to SEQ ID NO: 23, preferably under control of a bla promoter, for instance the bla promoter shown in SEQ ID NO: 24. Each of the first and second DNA plasmids independently further comprises at least one of a promoter sequence, enhancer sequence, and a polynucleotide sequence encoding a signal peptide sequence operably linked to the first polynucleotide sequence or the second polynucleotide sequence. Preferably, each of the first and second DNA plasmids comprises an upstream sequence operably linked to the first polynucleotide or the second polynucleotide, wherein the upstream sequence comprises, from 5' end to 3' end, a promoter sequence of SEQ ID NO: 18 or 19, an enhancer sequence, and a polynucleotide sequence encoding a signal peptide sequence having the amino acid sequence of SEQ ID NO: 9 or 15. Each of the first and second DNA plasmids can also comprise a polyadenylation signal located downstream of the coding sequence of the HBV antigen, such as the bGH polyadenylation signal of SEQ ID NO: 20.

In one particular embodiment of the application, the first vector is a viral vector and the second vector is a viral vector. Preferably, each of the viral vectors is an adenoviral vector, more preferably an Ad26 or Ad35 vector, comprising an expression cassette including the polynucleotide encoding an HBV pol antigen or an truncated HBV core antigen of the application; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5' end to 3' end, a promoter sequence, preferably a CMV promoter sequence of SEQ ID NO: 19, an enhancer sequence, preferably an ApoAI gene fragment sequence of SEQ ID NO: 12, and a polynucleotide sequence encoding a signal peptide sequence, preferably an immunoglobulin secretion signal having the amino acid sequence of SEQ ID NO: 15; and a downstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising a polyadenylation signal, preferably a SV40 polyadenylation signal of SEQ ID NO: 13.

In another preferred embodiment, the first and second polynucleotides are present in a single vector, e.g., DNA plasmid or viral vector. Preferably, the single vector is an adenoviral vector, more preferably an Ad26 vector, comprising an expression cassette including a

CA 03141003 2021-12-8

polynucleotide encoding an HBV pol antigen and a truncated HBV core antigen of the application, preferably encoding an HBV pol antigen and a truncated HBV core antigen of the application as a fusion protein; an upstream sequence operably linked to the polynucleotide encoding the HBV pol and truncated core antigens comprising, from 5' end to 3' end, a promoter sequence, preferably a CMV promoter sequence of SEQ ID NO: 19, an enhancer sequence, preferably an ApoAI gene fragment sequence of SEQ ID NO: 12, and a polynucleotide sequence encoding a signal peptide sequence, preferably an immunoglobulin secretion signal having the amino acid sequence of SEQ ID NO: 15; and a downstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising a polyadenylation signal, preferably a SV40 polyadenylation signal of SEQ ID NO: 13.

When a therapeutic combination of the application comprises a first vector, such as a DNA plasmid or viral vector, and a second vector, such as a DNA plasmid or viral vector, the amount of each of the first and second vectors is not particularly limited. For example, the first DNA plasmid and the second DNA plasmid can be present in a ratio of 10:1 to 1:10, by weight, such as 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, by weight. Preferably, the first and second DNA plasmids are present in a ratio of 1:1, by weight. The therapeutic combination of the application can further comprise a third vector encoding a third active agent useful for treating an HBV infection.

Compositions and therapeutic combinations of the application can comprise additional polynucleotides or vectors encoding additional HBV antigens and/or additional HBV antigens or immunogenic fragments thereof, such as an HBsAg, an HBV L protein or HBV envelope protein, or a polynucleotide sequence encoding thereof. However, in particular embodiments, the compositions and therapeutic combinations of the application do not comprise certain antigens.

In a particular embodiment, a composition or therapeutic combination or kit of the application does not comprise a HBsAg or a polynucleotide sequence encoding the HBsAg.

In another particular embodiment, a composition or therapeutic combination or kit of the application does not comprise an HBV L protein or a polynucleotide sequence encoding the HBV L protein.

In yet another particular embodiment of the application, a composition or therapeutic combination of the application does not comprise an HBV envelope protein or a polynucleotide sequence encoding the HBV envelope protein.

CA 03141003 2021-12-8

Compositions and therapeutic combinations of the application can also comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is non-toxic and should not interfere with the efficacy of the active ingredient. Pharmaceutically acceptable carriers can include one or more excipients such as binders, disintegrants, swelling agents,
5 suspending agents, emulsifying agents, wetting agents, lubricants, flavorants, sweeteners, preservatives, dyes, solubilizers and coatings. Pharmaceutically acceptable carriers can include vehicles, such as lipid nanoparticles (LNPs). The precise nature of the carrier or other material can depend on the route of administration, e.g., intramuscular, intradermal, subcutaneous, oral, intravenous, cutaneous, intramucosal (e.g., gut), intranasal or intraperitoneal routes. For liquid
10 injectable preparations, for example, suspensions and solutions, suitable carriers and additives include water, glycols, oils, alcohols, preservatives, coloring agents and the like. For solid oral preparations, for example, powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. For nasal sprays/inhalant mixtures, the aqueous solution/suspension can
15 comprise water, glycols, oils, emollients, stabilizers, wetting agents, preservatives, aromatics, flavors, and the like as suitable carriers and additives.

Compositions and therapeutic combinations of the application can be formulated in any matter suitable for administration to a subject to facilitate administration and improve efficacy, including, but not limited to, oral (enteral) administration and parenteral injections. The
20 parenteral injections include intravenous injection or infusion, subcutaneous injection, intradermal injection, and intramuscular injection. Compositions of the application can also be formulated for other routes of administration including transmucosal, ocular, rectal, long acting implantation, sublingual administration, under the tongue, from oral mucosa bypassing the portal circulation, inhalation, or intranasal.

25 In a preferred embodiment of the application, compositions and therapeutic combinations of the application are formulated for parental injection, preferably subcutaneous, intradermal injection, or intramuscular injection, more preferably intramuscular injection.

According to embodiments of the application, compositions and therapeutic combinations for administration will typically comprise a buffered solution in a pharmaceutically acceptable
30 carrier, e.g., an aqueous carrier such as buffered saline and the like, e.g., phosphate buffered saline (PBS). The compositions and therapeutic combinations can also contain pharmaceutically

CA 03141003 2021-12-8

acceptable substances as required to approximate physiological conditions such as pH adjusting and buffering agents. For example, a composition or therapeutic combination of the application comprising plasmid DNA can contain phosphate buffered saline (PBS) as the pharmaceutically acceptable carrier. The plasmid DNA can be present in a concentration of, e.g., 0.5 mg/mL to 5
5 mg/mL, such as 0.5 mg/mL 1, mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, or 5 mg/mL, preferably at 1 mg/mL.

Compositions and therapeutic combinations of the application can be formulated as a vaccine (also referred to as an "immunogenic composition") according to methods well known in the art. Such compositions can include adjuvants to enhance immune responses. The optimal
10 ratios of each component in the formulation can be determined by techniques well known to those skilled in the art in view of the present disclosure.

In a particular embodiment of the application, a composition or therapeutic combination is a DNA vaccine. DNA vaccines typically comprise bacterial plasmids containing a polynucleotide encoding an antigen of interest under control of a strong eukaryotic promoter. Once the plasmids
15 are delivered to the cell cytoplasm of the host, the encoded antigen is produced and processed endogenously. The resulting antigen typically induces both humoral and cell-medicated immune responses. DNA vaccines are advantageous at least because they offer improved safety, are temperature stable, can be easily adapted to express antigenic variants, and are simple to produce. Any of the DNA plasmids of the application can be used to prepare such a DNA vaccine.
20 In other particular embodiments of the application, a composition or therapeutic combination is an RNA vaccine. RNA vaccines typically comprise at least one single-stranded RNA molecule encoding an antigen of interest, e.g., a fusion protein or HBV antigen according to the application. Once the RNA is delivered to the cell cytoplasm of the host, the encoded antigen is produced and processed endogenously, inducing both humoral and cell-mediated immune
25 responses, similar to a DNA vaccine. The RNA sequence can be codon optimized to improve translation efficiency. The RNA molecule can be modified by any method known in the art in view of the present disclosure to enhance stability and/or translation, such by adding a polyA tail, e.g., of at least 30 adenosine residues; and/or capping the 5-end with a modified ribonucleotide, e.g., 7-methylguanosine cap, which can be incorporated during RNA synthesis or enzymatically
30 engineered after RNA transcription. An RNA vaccine can also be self-replicating RNA vaccine developed from an alphavirus expression vector. Self-replicating RNA vaccines comprise a

CA 03141003 2021-12-8

replicase RNA molecule derived from a virus belonging to the alphavirus family with a subgenomic promoter that controls replication of the fusion protein or HBV antigen RNA followed by an artificial poly A tail located downstream of the replicase.

In certain embodiments, a further adjuvant can be included in a composition or therapeutic combination of the application, or co-administered with a composition or therapeutic combination of the application. Use of another adjuvant is optional, and can further enhance immune responses when the composition is used for vaccination purposes. Other adjuvants suitable for co-administration or inclusion in compositions in accordance with the application should preferably be ones that are potentially safe, well tolerated and effective in humans. An adjuvant can be a small molecule or antibody including, but not limited to, immune checkpoint inhibitors (e.g., anti-PD1, anti-TIM-3, etc.), toll-like receptor agonists (e.g., TLR7 agonists and/or TLR8 agonists), RIG-1 agonists, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, and IL-7-hyFc. For example, adjuvants can e.g., be chosen from among the following anti-HBV agents: HBV DNA polymerase inhibitors; Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Interferon alpha receptor ligands; Hyaluronidase inhibitors; Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; Antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more particularly anti-HBV siRNA; Endonuclease modulators; Inhibitors of ribonucleotide reductase; Hepatitis B virus E antigen inhibitors; HBV antibodies targeting the surface antigens of the hepatitis B virus; HBV antibodies; CCR2 chemokine antagonists; Thymosin agonists; Cytokines, such as IL12; Capsid Assembly Modulators, Nucleoprotein inhibitors (HBV core or capsid protein inhibitors); Nucleic Acid Polymers (NAPs); Stimulators of retinoic acid-inducible gene 1; Stimulators of NOD2; Recombinant thymosin alpha-1; Hepatitis B virus replication inhibitors; PI3K inhibitors; cccDNA inhibitors; immune checkpoint inhibitors, such as PD-L1 inhibitors, PD-1 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, Lag3 inhibitors, CTLA-4 inhibitors; Agonists of co-stimulatory receptors that are expressed on immune cells (more particularly T cells), such as CD27 and CD28; BTK inhibitors; Other drugs for treating HBV; IDO inhibitors; Arginase inhibitors; and KDM5 inhibitors.

In certain embodiments, a therapeutic combination of the application further comprises an immune modulatory agent, such as an inhibitor of the PD-1/PD-L1 immune checkpoint axis, for example antibodies (or peptides) that bind to and/or inhibit the activity of PD-1 or the activity of PD-L1.

5 In certain embodiments, each of the first and second non-naturally occurring nucleic acid molecules is independently formulated with a lipid nanoparticle (LNP).

The application also provides methods of making compositions and therapeutic combinations of the application. A method of producing a composition or therapeutic combination comprises mixing an isolated polynucleotide encoding an HBV antigen, vector, 10 and/or polypeptide of the application with one or more pharmaceutically acceptable carriers. One of ordinary skill in the art will be familiar with conventional techniques used to prepare such compositions.

Methods of Inducing an Immune Response or Treating an HBV Infection

The application also provides methods of inducing an immune response against hepatitis 15 B virus (HBV) in a subject in need thereof, comprising administering to the subject an immunogenically effective amount of a composition or immunogenic composition of the application. Any of the compositions and therapeutic combinations of the application described herein can be used in the methods of the application.

As used herein, the term "infection" refers to the invasion of a host by a disease causing 20 agent. A disease causing agent is considered to be "infectious" when it is capable of invading a host, and replicating or propagating within the host. Examples of infectious agents include viruses, e.g., HBV and certain species of adenovirus, prions, bacteria, fungi, protozoa and the like. "HBV infection" specifically refers to invasion of a host organism, such as cells and tissues of the host organism, by HBV.

25 The phrase "inducing an immune response" when used with reference to the methods described herein encompasses causing a desired immune response or effect in a subject in need thereof against an infection, e.g., an HBV infection. "Inducing an immune response" also encompasses providing a therapeutic immunity for treating against a pathogenic agent, e.g., HBV. As used herein, the term "therapeutic immunity" or "therapeutic immune response" means that 30 the vaccinated subject is able to control an infection with the pathogenic agent against which the vaccination was done, for instance immunity against HBV infection conferred by vaccination

CA 03141003 2021-12-8

with HBV vaccine. In an embodiment, "inducing an immune response" means producing an immunity in a subject in need thereof, e.g., to provide a therapeutic effect against a disease, such as HBV infection. In certain embodiments, "inducing an immune response" refers to causing or improving cellular immunity, e.g., T cell response, against HBV infection. In certain
5 embodiments, "inducing an immune response" refers to causing or improving a humoral immune response against HBV infection. In certain embodiments, "inducing an immune response" refers to causing or improving a cellular and a humoral immune response against HBV infection.

As used herein, the term "protective immunity" or "protective immune response" means that the vaccinated subject is able to control an infection with the pathogenic agent against which
10 the vaccination was done. Usually, the subject having developed a "protective immune response" develops only mild to moderate clinical symptoms or no symptoms at all. Usually, a subject having a "protective immune response" or "protective immunity" against a certain agent will not die as a result of the infection with said agent.

Typically, the administration of compositions and therapeutic combinations of the
15 application will have a therapeutic aim to generate an immune response against HBV after HBV infection or development of symptoms characteristic of HBV infection, e.g., for therapeutic vaccination.

As used herein, "an immunogenically effective amount" or "immunologically effective amount" means an amount of a composition, polynucleotide, vector, or antigen sufficient to
20 induce a desired immune effect or immune response in a subject in need thereof. An immunogenically effective amount can be an amount sufficient to induce an immune response in a subject in need thereof. An immunogenically effective amount can be an amount sufficient to produce immunity in a subject in need thereof, e.g., provide a therapeutic effect against a disease such as HBV infection. An immunogenically effective amount can vary depending upon a variety
25 of factors, such as the physical condition of the subject, age, weight, health, etc.; the particular application, e.g., providing protective immunity or therapeutic immunity; and the particular disease, e.g., viral infection, for which immunity is desired. An immunogenically effective amount can readily be determined by one of ordinary skill in the art in view of the present disclosure.

30 In particular embodiments of the application, an immunogenically effective amount refers to the amount of a composition or therapeutic combination which is sufficient to achieve one, two,

CA 03141003 2021-12-8

three, four, or more of the following effects: (i) reduce or ameliorate the severity of an HBV infection or a symptom associated therewith; (ii) reduce the duration of an HBV infection or symptom associated therewith; (iii) prevent the progression of an HBV infection or symptom associated therewith; (iv) cause regression of an HBV infection or symptom associated therewith; (v) prevent the development or onset of an HBV infection, or symptom associated therewith; (vi) prevent the recurrence of an HBV infection or symptom associated therewith; (vii) reduce hospitalization of a subject having an HBV infection; (viii) reduce hospitalization length of a subject having an HBV infection; (ix) increase the survival of a subject with an HBV infection; (x) eliminate an HBV infection in a subject; (xi) inhibit or reduce HBV replication in a subject; and/or (xii) enhance or improve the prophylactic or therapeutic effect(s) of another therapy.

An immunogenically effective amount can also be an amount sufficient to reduce HBsAg levels consistent with evolution to clinical seroconversion; achieve sustained HBsAg clearance associated with reduction of infected hepatocytes by a subject's immune system; induce HBV-antigen specific activated T-cell populations; and/or achieve persistent loss of HBsAg within 12 months. Examples of a target index include lower HBsAg below a threshold of 500 copies of HBsAg international units (IU) and/or higher CD8 counts.

As general guidance, an immunogenically effective amount when used with reference to a DNA plasmid can range from about 0.1 mg/mL to 10 mg/mL of DNA plasmid total, such as 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL. 0.75 mg/mL 1 mg/mL, 1.5 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL. Preferably, an immunogenically effective amount of DNA plasmid is less than 8 mg/mL, more preferably less than 6 mg/mL, even more preferably 3-4 mg/mL. An immunogenically effective amount can be from one vector or plasmid, or from multiple vectors or plasmids. As further general guidance, an immunogenically effective amount when used with reference to a peptide can range from about 10 µg to 1 mg per administration, such as 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 9000, or 1000 µg per administration. An immunogenically effective amount can be administered in a single composition, or in multiple compositions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 compositions (e.g., tablets, capsules or injectables, or any composition adapted to intradermal delivery, e.g., to intradermal delivery using an intradermal delivery patch), wherein the administration of the multiple capsules or injections collectively provides a subject with an immunogenically effective amount. For example, when two DNA plasmids are used, an

CA 03141003 2021-12-8

immunogenically effective amount can be 3-4 mg/mL, with 1.5-2 mg/mL of each plasmid. As yet further general guidance, an immunogenically effective amount when used with reference to an PD-L1 inhibitor can range from about 0.005 mg/kg to 100 mg/kg. In particular, an effective therapeutic daily amount of an PD-L1 inhibitor would be 25 mg/kg BID (twice a day) or 50 mg/kg BID. In particular, an effective therapeutic daily amount would be 50 mg/kg QD (once a day) or 100 mg/kg QD. It is also possible to administer an immunogenically effective amount to a subject, and subsequently administer another dose of an immunogenically effective amount to the same subject, in a so-called prime-boost regimen. This general concept of a prime-boost regimen is well known to the skilled person in the vaccine field. Further booster administrations can optionally be added to the regimen, as needed.

A therapeutic combination comprising two DNA plasmids, e.g., a first DNA plasmid encoding an HBV core antigen and second DNA plasmid encoding an HBV pol antigen, can be administered to a subject by mixing both plasmids and delivering the mixture to a single anatomic site. Alternatively, two separate immunizations each delivering a single expression plasmid can be performed. In such embodiments, whether both plasmids are administered in a single immunization as a mixture of in two separate immunizations, the first DNA plasmid and the second DNA plasmid can be administered in a ratio of 10:1 to 1:10, by weight, such as 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, by weight. Preferably, the first and second DNA plasmids are administered in a ratio of 1:1, by weight.

Preferably, a subject to be treated according to the methods of the application is an HBV-infected subject, in particular a subject having chronic HBV infection. Acute HBV infection is characterized by an efficient activation of the innate immune system complemented with a subsequent broad adaptive response (e.g., HBV-specific T-cells, neutralizing antibodies), which usually results in successful suppression of replication or removal of infected hepatocytes. In contrast, such responses are impaired or diminished due to high viral and antigen load, e.g., HBV envelope proteins are produced in abundance and can be released in sub-viral particles in 1,000-fold excess to infectious virus.

Chronic HBV infection is described in phases characterized by viral load, liver enzyme levels (necroinflammatory activity), HBeAg, or HBsAg load or presence of antibodies to these antigens. cccDNA levels stay relatively constant at approximately 10 to 50 copies per cell, even though viremia can vary considerably. The persistence of the cccDNA species leads to

CA 03141003 2021-12-8

chronicity. More specifically, the phases of chronic HBV infection include: (i) the immune-tolerant phase characterized by high viral load and normal or minimally elevated liver enzymes; (ii) the immune activation HBeAg-positive phase in which lower or declining levels of viral replication with significantly elevated liver enzymes are observed; (iii) the inactive HBsAg carrier
5 phase, which is a low replicative state with low viral loads and normal liver enzyme levels in the serum that may follow HBeAg seroconversion; and (iv) the HBeAg-negative phase in which viral replication occurs periodically (reactivation) with concomitant fluctuations in liver enzyme levels, mutations in the pre-core and/or basal core promoter are common, such that HBeAg is not produced by the infected cell.

10 As used herein, "chronic HBV infection" refers to a subject having the detectable presence of HBV for more than 6 months. A subject having a chronic HBV infection can be in any phase of chronic HBV infection. Chronic HBV infection is understood in accordance with its ordinary meaning in the field. Chronic HBV infection can for example be characterized by the persistence of HBsAg for 6 months or more after acute HBV infection. For example, a chronic HBV
15 infection referred to herein follows the definition published by the Centers for Disease Control and Prevention (CDC), according to which a chronic HBV infection can be characterized by laboratory criteria such as: (i) negative for IgM antibodies to hepatitis B core antigen (IgM anti-HBc) and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), or nucleic acid test for hepatitis B virus DNA, or (ii) positive for HBsAg or nucleic acid test for
20 HBV DNA, or positive for HBeAg two times at least 6 months apart.

Preferably, an immunogenically effective amount refers to the amount of a composition or therapeutic combination of the application which is sufficient to treat chronic HBV infection.

In some embodiments, a subject having chronic HBV infection is undergoing nucleoside analog (NUC) treatment, and is NUC-suppressed. As used herein, "NUC-suppressed" refers to a
25 subject having an undetectable viral level of HBV and stable alanine aminotransferase (ALT) levels for at least six months. Examples of nucleoside/nucleotide analog treatment include HBV polymerase inhibitors, such as entacavir and tenofovir. Preferably, a subject having chronic HBV infection does not have advanced hepatic fibrosis or cirrhosis. Such subject would typically have a METAVIR score of less than 3 for fibrosis and a fibroscan result of less than 9 kPa. The
30 METAVIR score is a scoring system that is commonly used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis B. The

CA 03141003 2021-12-8

scoring system assigns two standardized numbers: one reflecting the degree of inflammation and one reflecting the degree of fibrosis.

It is believed that elimination or reduction of chronic HBV may allow early disease interception of severe liver disease, including virus-induced cirrhosis and hepatocellular carcinoma. Thus, the methods of the application can also be used as therapy to treat HBV-induced diseases. Examples of HBV-induced diseases include, but are not limited to cirrhosis, cancer (e.g., hepatocellular carcinoma), and fibrosis, particularly advanced fibrosis characterized by a METAVIR score of 3 or higher for fibrosis. In such embodiments, an immunogenically effective amount is an amount sufficient to achieve persistent loss of HBsAg within 12 months and significant decrease in clinical disease (e.g., cirrhosis, hepatocellular carcinoma, etc.).

Methods according to embodiments of the application further comprises administering to the subject in need thereof another immunogenic agent (such as another HBV antigen or other antigen) or another anti-HBV agent (such as a nucleoside analog or other anti-HBV agent) in combination with a composition of the application. For example, another anti-HBV agent or immunogenic agent can be a small molecule or antibody including, but not limited to, immune checkpoint inhibitors (e.g., anti-PD1, anti-TIM-3, etc.), toll-like receptor agonists (e.g., TLR7 agonists and/oror TLR8 agonists), RIG-1 agonists, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, IL12 genetic adjuvant, IL-7-hyFc; CAR-T which bind HBV env (S-CAR cells); capsid assembly modulators; cccDNA inhibitors, HBV polymerase inhibitors (e.g., entecavir and tenofovir). The one or other anti-HBV active agents can be, for example, a small molecule, an antibody or antigen binding fragment thereof, a polypeptide, protein, or nucleic acid. The one or other anti-HBV agents can e.g., be chosen from among HBV DNA polymerase inhibitors; Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Interferon alpha receptor ligands; Hyaluronidase inhibitors; Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; Antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more particularly anti-HBV siRNA; Endonuclease modulators; Inhibitors of ribonucleotide reductase; Hepatitis B virus E antigen inhibitors; HBV antibodies targeting the surface antigens of the hepatitis B virus; HBV antibodies; CCR2 chemokine antagonists; Thymosin agonists;

CA 03141003 2021-12-8

Cytokines, such as IL12; Capsid Assembly Modulators, Nucleoprotein inhibitors (HBV core or capsid protein inhibitors); Nucleic Acid Polymers (NAPs); Stimulators of retinoic acid-inducible gene 1; Stimulators of NOD2; Recombinant thymosin alpha-1; Hepatitis B virus replication inhibitors; PI3K inhibitors; cccDNA inhibitors; immune checkpoint inhibitors, such as PD-L1 inhibitors, PD-1 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, Lag3 inhibitors, and CTLA-4 inhibitors; Agonists of co-stimulatory receptors that are expressed on immune cells (more particularly T cells), such as CD27, CD28; BTK inhibitors; Other drugs for treating HBV; IDO inhibitors; Arginase inhibitors; and KDM5 inhibitors.

In certain embodiments, a method described herein further comprises administering to the subject in need thereof an immune modulatory agent, such as an inhibitor of the PD-1/PD-L1 immune checkpoint axis, for example antibodies (or peptides) that bind to and/or inhibit the activity of PD-1 or the activity of PD-L1.

Methods of Delivery

Compositions and therapeutic combinations of the application can be administered to a subject by any method known in the art in view of the present disclosure, including, but not limited to, parenteral administration (e.g., intramuscular, subcutaneous, intravenous, or intradermal injection), oral administration, transdermal administration, and nasal administration. Preferably, compositions and therapeutic combinations are administered parenterally (e.g., by intramuscular injection or intradermal injection) or transdermally.

In some embodiments of the application in which a composition or therapeutic combination comprises one or more DNA plasmids, administration can be by injection through the skin, e.g., intramuscular or intradermal injection, preferably intramuscular injection. Intramuscular injection can be combined with electroporation, i.e., application of an electric field to facilitate delivery of the DNA plasmids to cells. As used herein, the term "electroporation" refers to the use of a transmembrane electric field pulse to induce microscopic pathways (pores) in a bio-membrane. During in vivo electroporation, electrical fields of appropriate magnitude and duration are applied to cells, inducing a transient state of enhanced cell membrane permeability, thus enabling the cellular uptake of molecules unable to cross cell membranes on their own. Creation of such pores by electroporation facilitates passage of biomolecules, such as plasmids, oligonucleotides, siRNAs, drugs, etc., from one side of a cellular membrane to the other. In vivo electroporation for the delivery of DNA vaccines has been shown to significantly

CA 03141003 2021-12-8

increase plasmid uptake by host cells, while also leading to mild-to-moderate inflammation at the injection site. As a result, transfection efficiency and immune response are significantly improved (e.g., up to 1,000 fold and 100 fold respectively) with intradermal or intramuscular electroporation, in comparison to conventional injection.

5 In a typical embodiment, electroporation is combined with intramuscular injection. However, it is also possible to combine electroporation with other forms of parenteral administration, e.g., intradermal injection, subcutaneous injection, etc.

Administration of a composition, therapeutic combination or vaccine of the application via electroporation can be accomplished using electroporation devices that can be configured to
10 deliver to a desired tissue of a mammal a pulse of energy effective to cause reversible pores to form in cell membranes. The electroporation device can include an electroporation component and an electrode assembly or handle assembly. The electroporation component can include one or more of the following components of electroporation devices: controller, current waveform generator, impedance tester, waveform logger, input element, status reporting element,
15 communication port, memory component, power source, and power switch. Electroporation can be accomplished using an in vivo electroporation device. Examples of electroporation devices and electroporation methods that can facilitate delivery of compositions and therapeutic combinations of the application, particularly those comprising DNA plasmids, include CELLECTRA® (Inovio Pharmaceuticals, Blue Bell, PA), Elgen electroporator (Inovio
20 Pharmaceuticals, Inc.) Tri-GridTM delivery system (Ichor Medical Systems, Inc., San Diego, CA 92121) and those described in U.S. Patent No. 7,664,545, U.S. Patent No. 8,209,006, U.S. Patent No. 9,452,285, U.S. Patent No. 5,273,525, U.S. Patent No. 6,110,161, U.S. Patent No. 6,261,281, U.S. Patent No. 6,958,060, and U.S. Patent No. 6,939,862, U.S. Patent No. 7,328,064, U.S. Patent No. 6,041,252, U.S. Patent No. 5,873,849, U.S. Patent No. 6,278,895, U.S. Patent
25 No. 6,319,901, U.S. Patent No. 6,912,417, U.S. Patent No. 8,187,249, U.S. Patent No. 9,364,664, U.S. Patent No. 9,802,035, U.S. Patent No. 6,117,660, and International Patent Application Publication WO2017172838, all of which are herein incorporated by reference in their entireties. Other examples of in vivo electroporation devices are described in International Patent Application entitled "Method and Apparatus for the Delivery of Hepatitis B Virus (HBV)
30 Vaccines," filed on the same day as this application with the Attorney Docket Number 688097-405WO, the contents of which are hereby incorporated by reference in their entireties. Also

CA 03141003 2021-12-8

contemplated by the application for delivery of the compositions and therapeutic combinations of the application are use of a pulsed electric field, for instance as described in, e.g., U.S. Patent No. 6,697,669, which is herein incorporated by reference in its entirety.

In other embodiments of the application in which a composition or therapeutic combination comprises one or more DNA plasmids, the method of administration is transdermal. Transdermal administration can be combined with epidermal skin abrasion to facilitate delivery of the DNA plasmids to cells. For example, a dermatological patch can be used for epidermal skin abrasion. Upon removal of the dermatological patch, the composition or therapeutic combination can be deposited on the abraised skin.

Methods of delivery are not limited to the above described embodiments, and any means for intracellular delivery can be used. Other methods of intracellular delivery contemplated by the methods of the application include, but are not limited to, liposome encapsulation, lipid nanoparticles (LNPs), etc. Additionally, PD-L1 inhibitors and compositions thereof as described herein can be administered systemically or topically, and are preferably administered via oral administration.

Adjuvants

In some embodiments of the application, a method of inducing an immune response against HBV further comprises administering an adjuvant. The terms "adjuvant" and "immune stimulant" are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system. In this context, an adjuvant is used to enhance an immune response to HBV antigens and antigenic HBV polypeptides of the application.

According to embodiments of the application, an adjuvant can be present in a therapeutic combination or composition of the application, or administered in a separate composition. An adjuvant can be, e.g., a small molecule or an antibody. Examples of adjuvants suitable for use in the application include, but are not limited to, immune checkpoint inhibitors (e.g., anti-PD1, anti-TIM-3, etc.), toll-like receptor agonists (e.g., TLR7 and/or TLR8 agonists), RIG-1 agonists, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, IL12 genetic adjuvant, and IL-7-hyFc. Examples of adjuvants can e.g., be chosen from among the following anti-HBV agents: HBV DNA polymerase inhibitors; Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Interferon alpha receptor ligands; Hyaluronidase inhibitors;

CA 03141003 2021-12-8

Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; Antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more particularly anti-HBV siRNA; Endonuclease modulators;
5 Inhibitors of ribonucleotide reductase; Hepatitis B virus E antigen inhibitors; HBV antibodies targeting the surface antigens of the hepatitis B virus; HBV antibodies; CCR2 chemokine antagonists; Thymosin agonists; Cytokines, such as IL12; Capsid Assembly Modulators, Nucleoprotein inhibitors (HBV core or capsid protein inhibitors); Nucleic Acid Polymers (NAPs); Stimulators of retinoic acid-inducible gene 1; Stimulators of NOD2; Recombinant
10 thymosin alpha-1; Hepatitis B virus replication inhibitors; PI3K inhibitors; cccDNA inhibitors; immune checkpoint inhibitors, such as PD-L1 inhibitors, PD-1 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, Lag3 inhibitors, and CTLA-4 inhibitors; Agonists of co-stimulatory receptors that are expressed on immune cells (more particularly T cells), such as CD27, CD28; BTK inhibitors; Other drugs for treating HBV; IDO inhibitors; Arginase inhibitors; and KDM5
15 inhibitors.

Compositions and therapeutic combinations of the application can also be administered in combination with at least one other anti-HBV agent. Examples of anti-HBV agents suitable for use with the application include, but are not limited to small molecules, antibodies, and/or CAR-T therapies which bind HBV env (S-CAR cells), capsid assembly modulators, TLR agonists
20 (e.g., TLR7 and/or TLR8 agonists), cccDNA inhibitors, HBV polymerase inhibitors (e.g., entecavir and tenofovir), and/or immune checkpoint inhibitors, etc.

The at least one anti-HBV agent can e.g., be chosen from among HBV DNA polymerase inhibitors; Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Interferon alpha receptor ligands; Hyaluronidase inhibitors;
25 Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; Antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more particularly anti-HBV siRNA; Endonuclease modulators; Inhibitors of ribonucleotide reductase; Hepatitis B virus E antigen inhibitors; HBV antibodies
30 targeting the surface antigens of the hepatitis B virus; HBV antibodies; CCR2 chemokine antagonists; Thymosin agonists; Cytokines, such as IL12; Capsid Assembly Modulators,

CA 03141003 2021-12-8

Nucleoprotein inhibitors (HBV core or capsid protein inhibitors); Nucleic Acid Polymers (NAPs); Stimulators of retinoic acid-inducible gene 1; Stimulators of NOD2; Recombinant thymosin alpha-1; Hepatitis B virus replication inhibitors; PI3K inhibitors; cccDNA inhibitors; immune checkpoint inhibitors, such as PD-L1 inhibitors, PD-1 inhibitors, TIM-3 inhibitors,
5 TIGIT inhibitors, Lag3 inhibitors, and CTLA-4 inhibitors; Agonists of co-stimulatory receptors that are expressed on immune cells (more particularly T cells), such as CD27, CD28; BTK inhibitors; Other drugs for treating HBV; IDO inhibitors; Arginase inhibitors; and KDM5 inhibitors. Such anti-HBV agents can be administered with the compositions and therapeutic combinations of the application simultaneously or sequentially.

10 Methods of Prime/Boost Immunization

Embodiments of the application also contemplate administering an immunogenically effective amount of a composition or therapeutic combination to a subject, and subsequently administering another dose of an immunogenically effective amount of a composition or therapeutic combination to the same subject, in a so-called prime-boost regimen Thus, in an
15 embodiment, a composition or therapeutic combination of the application is a primer vaccine used for priming an immune response. In another embodiment, a composition or therapeutic combination of the application is a booster vaccine used for boosting an immune response. The priming and boosting vaccines of the application can be used in the methods of the application described herein. This general concept of a prime-boost regimen is well known to the skilled
20 person in the vaccine field. Any of the compositions and therapeutic combinations of the application described herein can be used as priming and/or boosting vaccines for priming and/or boosting an immune response against HBV.

In some embodiments of the application, a composition or therapeutic combination of the application can be administered for priming immunization. The composition or therapeutic
25 combination can be re-administered for boosting immunization. Further booster administrations of the composition or vaccine combination can optionally be added to the regimen, as needed. An adjuvant can be present in a composition of the application used for boosting immunization, present in a separate composition to be administered together with the composition or therapeutic combination of the application for the boosting immunization, or administered on its own as the
30 boosting immunization. In those embodiments in which an adjuvant is included in the regimen, the adjuvant is preferably used for boosting immunization.

CA 03141003 2021-12-8

An illustrative and non-limiting example of a prime-boost regimen includes administering a single dose of an immunogenically effective amount of a composition or therapeutic combination of the application to a subject to prime the immune response; and subsequently administering another dose of an immunogenically effective amount of a
5 composition or therapeutic combination of the application to boost the immune response, wherein the boosting immunization is first administered about two to six weeks, preferably four weeks after the priming immunization is initially administered. Optionally, about 10 to 14 weeks, preferably 12 weeks, after the priming immunization is initially administered, a further boosting immunization of the composition or therapeutic combination, or other adjuvant, is
10 administered.

Kits

Also provided herein is a kit comprising a therapeutic combination of the application. A kit can comprise the first polynucleotide, the second polynucleotide, and the at least one PD-L1 inhibitor in one or more separate compositions, or a kit can comprise the first polynucleotide, the
15 second polynucleotide, and the PD-L1 inhibitor in a single composition. A kit can further comprise one or more adjuvants or immune stimulants, and/or other anti-HBV agents.

The ability to induce or stimulate an anti-HBV immune response upon administration in an animal or human organism can be evaluated either in vitro or in vivo using a variety of assays which are standard in the art. For a general description of techniques available to evaluate the
20 onset and activation of an immune response, see for example Coligan et al. (1992 and 1994, Current Protocols in Immunology; ed. J Wiley & Sons Inc, National Institute of Health). Measurement of cellular immunity can be performed by measurement of cytokine profiles secreted by activated effector cells including those derived from CD4+ and CD8+ T-cells (e.g. quantification of IL-10 or IFN gamma-producing cells by ELISPOT), by determination of the
25 activation status of immune effector cells (e.g. T cell proliferation assays by a classical [3H] thymidine uptake or flow cytometry-based assays), by assaying for antigen-specific T lymphocytes in a sensitized subject (e.g. peptide-specific lysis in a cytotoxicity assay, etc.).

The ability to stimulate a cellular and/or a humoral response can be determined by antibody binding and/or competition in binding (see for example Harlow, 1989, Antibodies, Cold
30 Spring Harbor Press). For example, titers of antibodies produced in response to administration of a composition providing an immunogen can be measured by enzyme-linked immunosorbent

CA 03141003 2021-12-8

assay (ELISA). The immune responses can also be measured by neutralizing antibody assay, where a neutralization of a virus is defined as the loss of infectivity through reaction/inhibition/neutralization of the virus with specific antibody. The immune response can further be measured by Antibody-Dependent Cellular Phagocytosis (ADCP) Assay.

5

EMBODIMENTS

The invention provides also the following non-limiting embodiments.

Embodiment 1 is a therapeutic combination for use in treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising:

10 i) at least one of:

a) a truncated HBV core antigen consisting of an amino acid sequence that is at least 95%, such as at least 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 2,

b) a first non-naturally occurring nucleic acid molecule comprising a first

15 polynucleotide sequence encoding the truncated HBV core antigen

c) an HBV polymerase antigen having an amino acid sequence that is at least 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity, and

20 d) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding the HBV polymerase antigen; and

ii) a compound of formula (I):

R7 R6 R5 O R8 N R9 R1 N O O R2 R3 R4 R11 R10 X

(I)

CA 03141003 2021-12-8

In formula (I), R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$, $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-membered heteroaryl), and a ring;

5 R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H, halogen, C_{1-4}alkyl and C_{1-4}alkyl substituted with one or more F;

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one or more substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, C_{3-6}heterocycle, aryl and heteroaryl;

10 wherein C_{3-6}heterocycle is optionally substituted with one or more substituent selected from oxo, OH and CO_2H;

with the proviso that R^8 and R^9 are not both H;

or wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle optionally substituted with one or more substituents selected from C_{1-6}alkyl, oxo, OH and CO_2H;

15 R^{10} is selected from H, CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, $C(=O)NR^xR^y$, SO_2-C_{1-6}alkyl, aryl and heteroaryl;

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl; 20

X is N or CR^{12};

R^{12} is selected from H, F, Cl, CN, $C(=O)NR^xR^y$, aryl and heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one or more substituents

25 selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, $C(=O)NR^xR^y$ and SO_2-C_{1-6}alkyl; and

R^x and R^y are independently selected from H and C_{1-6}alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

30

CA 03141003 2021-12-8

Embodiment 2 is the therapeutic combination of embodiment 1, comprising at least one of the HBV polymerase antigen and the truncated HBV core antigen.

Embodiment 3 is the therapeutic combination of embodiment 2, comprising the HBV polymerase antigen and the truncated HBV core antigen.

5 Embodiment 4 is the therapeutic combination of embodiment 1, comprising at least one of the first non-naturally occurring nucleic acid molecule comprising the first polynucleotide sequence encoding the truncated HBV core antigen, and the second non-naturally occurring nucleic acid molecule comprising the second polynucleotide sequence encoding the HBV polymerase antigen.

10 Embodiment 5 is a therapeutic combination for use in treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising

i) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 95% identical to SEQ ID NO: 2; and

15 ii) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; and

20 iii) a compound of formula (I):

(I)

or a tautomer, stereoisomer, or pharmaceutically acceptable form thereof, wherein:

R^1 is an optionally substituted monocyclic or bicyclic ring;

25 R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H and C_{1-4}alkyl;

CA 03141003 2021-12-8

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one, two, or three substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, aryl and heteroaryl;

R^{10} is selected from H and CN;

5 R^{12} is selected from H, Cl, and CN; and

X is N.

Embodiment 6 is the therapeutic combination of embodiment 4 or 5, wherein the first non-naturally occurring nucleic acid molecule further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the truncated HBV core 10 antigen.

Embodiment 6a is the therapeutic combination of any one of embodiments 4 to 6, wherein the second non-naturally occurring nucleic acid molecule further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the HBV polymerase antigen.

15 Embodiment 6b is the therapeutic combination of embodiment 6 or 6a, wherein the signal sequence independently comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15.

Embodiment 6c is the therapeutic combination of embodiment 6 or 6a, wherein the signal sequence is independently encoded by the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID 20 NO: 14.

Embodiment 7 is the therapeutic combination of any one of embodiments 1-6c, wherein the HBV polymerase antigen comprises an amino acid sequence that is at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%, identical to SEQ ID NO: 7.

25 Embodiment 7a is the therapeutic combination of embodiment 7, wherein the HBV polymerase antigen comprises the amino acid sequence of SEQ ID NO: 7.

Embodiment 7b is the therapeutic combination of any one of embodiments 1 to 7a, wherein the truncated HBV core antigen consists of the amino acid sequence that is at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 30 99.9%, or 100%, identical to SEQ ID NO: 2.

CA 03141003 2021-12-8

Embodiment 7c is the therapeutic combination of embodiment 7b, wherein the truncated HBV antigen consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

Embodiment 8 is the therapeutic combination of any one of embodiments 1-7c, wherein each of the first and second non-naturally occurring nucleic acid molecules is a DNA molecule.

5 Embodiment 8a is the therapeutic combination of embodiment 8, wherein the DNA molecule is present on a DNA vector.

Embodiment 8b is the therapeutic combination of embodiment 8a, wherein the DNA vector is selected from the group consisting of DNA plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, and closed linear deoxyribonucleic acid.

10 Embodiment 8c is the therapeutic combination of embodiment 8, wherein the DNA molecule is present on a viral vector.

Embodiment 8d is the therapeutic combination of embodiment 8c, wherein the viral vector is selected from the group consisting of bacteriophages, animal viruses, and plant viruses.

Embodiment 8e is the therapeutic combination of any one of embodiments 1-7c, wherein
15 each of the first and second non-naturally occurring nucleic acid molecules is an RNA molecule.

Embodiment 8f is the therapeutic combination of embodiment 8e, wherein the RNA molecule is an RNA replicon, preferably a self-replicating RNA replicon, an mRNA replicon, a modified mRNA replicon, or self-amplifying mRNA.

Embodiment 8g is the therapeutic combination of any one of embodiments 1 to 8f,
20 wherein each of the first and second non-naturally occurring nucleic acid molecules is independently formulated with a lipid composition, preferably a lipid nanoparticle (LNP).

Embodiment 9 is the therapeutic combination of any one of embodiments 4-8g, comprising the first non-naturally occurring nucleic acid molecule and the second non-naturally occurring nucleic acid molecule in the same non-naturally occurring nucleic acid molecule.

25 Embodiment 10 is the therapeutic combination of any one of embodiments 4-8g, comprising the first non-naturally occurring nucleic acid molecule and the second non-naturally occurring nucleic acid molecule in two different non-naturally occurring nucleic acid molecules.

Embodiment 11 is the therapeutic combination of any one of embodiments 4-10, wherein the first polynucleotide sequence comprises a polynucleotide sequence having at least 90%, such
30 as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

CA 03141003 2021-12-8

Embodiment 11a is the therapeutic combination of embodiment 11, wherein the first polynucleotide sequence comprises a polynucleotide sequence having at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%, sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.

5 Embodiment 12 is the therapeutic combination of embodiment 11a, wherein the first polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

Embodiment 13 is the therapeutic combination of any one of embodiments 4 to 12, wherein the second polynucleotide sequence comprises a polynucleotide sequence having at least 10 90%, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.

Embodiment 13a the therapeutic combination of embodiment 13, wherein the second polynucleotide sequence comprises a polynucleotide sequence having at least 98%, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 15 100%, sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.

Embodiment 14 is the therapeutic combination of embodiment 13a, wherein the second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

Embodiment 15 is the therapeutic combination of any one of embodiments 1 to 14, 20 wherein the compound of formula (I) is selected from the group consisting of the exemplified compounds, particularly compounds 7, 8, 9, 10, 11, 12, 101, 103, 202, 203, or 204, or a tautomer or stereisomeric form, or a pharmaceutically acceptable salt thereof.

Embodiment 15a is the therapeutic combination of any one of embodiments 1 to 14, wherein the compound of formula (I) is selected from the group consisting of the exemplified 25 compounds, particularly compounds 205, 207, or 209, or a tautomer or stereisomeric form, or a pharmaceutically acceptable salt thereof.

Embodiment 15b is the immunogenic combination of any one of embodiments 1 to 15a, further comprising one or more other anti-HBV agents.

Embodiment 15c is the immunogenic combination of embodiment 15b, wherein the anti-30 HBV agents are HBV DNA polymerase inhibitors; Immunomodulators; Toll-like receptor 7 modulators; Toll-like receptor 8 modulators; Toll-like receptor 3 modulators; Interferon alpha

CA 03141003 2021-12-8

receptor ligands; Hyaluronidase inhibitors; Modulators of IL-10; HBsAg inhibitors; Toll like receptor 9 modulators; Cyclophilin inhibitors; HBV Prophylactic vaccines; HBV Therapeutic vaccines; HBV viral entry inhibitors; Antisense oligonucleotides targeting viral mRNA, more particularly anti-HBV antisense oligonucleotides; short interfering RNAs (siRNA), more
5 particularly anti-HBV siRNA; Endonuclease modulators; Inhibitors of ribonucleotide reductase; Hepatitis B virus E antigen inhibitors; HBV antibodies targeting the surface antigens of the hepatitis B virus; HBV antibodies; CCR2 chemokine antagonists; Thymosin agonists; Cytokines, such as IL12; Capsid Assembly Modulators, Nucleoprotein inhibitors (HBV core or capsid protein inhibitors); Nucleic Acid Polymers (NAPs); Stimulators of retinoic acid-inducible gene
10 1; Stimulators of NOD2; Recombinant thymosin alpha-1; Hepatitis B virus replication inhibitors; PI3K inhibitors; cccDNA inhibitors; immune checkpoint inhibitors, such as PD-L1 inhibitors, PD-1 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, Lag3 inhibitors, CTLA-4 inhibitors; Agonists of co-stimulatory receptors that are expressed on immune cells (more particularly T cells), such as CD27 and CD28; BTK inhibitors; Other drugs for treating HBV; IDO inhibitors;
15 Arginase inhibitors; or KDM5 inhibitors.

Embodiment 16 is a kit comprising the therapeutic combination of any one of embodiments 1 to 15c, and instructions for using the therapeutic combination in treating a hepatitis B virus (HBV) infection in a subject in need thereof.

Embodiment 17 is a method of treating a hepatitis B virus (HBV) infection in a subject in
20 need thereof, comprising administering to the subject the therapeutic combination of any one of embodiments 1 to 15b.

Embodiment 17a is the method of embodiment 17, wherein the treatment induces an immune response against a hepatitis B virus in a subject in need thereof, preferably the subject has chronic HBV infection.

25 Embodiment 17b is the method of embodiment 17 or 17a, wherein the subject has chronic HBV infection.

Embodiment 17c is the method of any one of embodiments 17 to 17b, wherein the subject is in need of a treatment of an HBV-induced disease selected from the group consisting of advanced fibrosis, cirrhosis and hepatocellular carcinoma (HCC).

CA 03141003 2021-12-8

Embodiment 18 is the method of any one of embodiments 17-17c, wherein the therapeutic combination is administered by injection through the skin, e.g., intramuscular or intradermal injection, preferably intramuscular injection.

Embodiment 19 is the method of embodiment 18, wherein the therapeutic combination
5 comprises at least one of the first and second non-naturally occurring nucleic acid molecules.

Embodiment 19a is the method of embodiment 19, wherein the therapeutic combination comprises the first and second non-naturally occurring nucleic acid molecules.

Embodiment 20 is the method of embodiment 19 or 19a, wherein the non-naturally occurring nucleic acid molecules are administered to the subject by intramuscular injection in
10 combination with electroporation.

Embodiment 21 is the method of embodiment 19 or 19a, wherein the non-naturally occurring nucleic acid molecules are administered to the subject by a lipid composition, preferably by a lipid nanoparticle.

15 It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the present description.

20

EXAMPLES

Synthesis Examples

CA 03141003 2021-12-8

Several methods for preparing the compounds of formula (I) described herein are illustrated in the following examples. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification, or alternatively can be synthesized by a skilled person by using well-known methods.

Example 1: Preparation of Compounds of the Disclosure

Scheme 1. Synthesis of Compound 7

Synthesis of 1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-3-(hydroxymethyl)pyridin-2(1*H*)-one

To a solution of 3-(hydroxymethyl)pyridin-2(1*H*)-one (5 g, 39.960 mmol) in 1,4-dioxane (50 mL) was added 6-iodo-2,3-dihydrobenzo[*b*][1,4]dioxine (12.566 g, 47.952 mmol), CuI (765 mg, 3.996 mmol), K_3PO_4 (16.964 g, 79.920 mmol) and *N,N'*-dimethylethylenediamine (929 mg,

CA 03141003 2021-12-8

7.992 mmol) under N_2 atmosphere. The resulting mixture was maintained under nitrogen and stirred at 110 °C for overnight. After cooling down to rt, the reaction was quenched with water (100 mL). The resulting mixture was extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, the solids were removed by filtration and the filtrate was concentrated under reduced pressure. The crude was purified by silica gel chromatography (0 to 15% CH_3OH/ CH_2Cl_2) to afford the titled compound as a white solid (4.4 g, 42%). LC/MS: mass calcd. for $C_{14}H_{13}NO_4$: 259.08, found: 260.15 [M+H]+.

Synthesis of 3-(chloromethyl)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyridin-2(1*H*)-one

$SOCl_2$, CH_2Cl_2

2 → 3

To a solution of 1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-3-(hydroxymethyl)pyridin-2(1*H*)-one (2 g, 7.714 mmol) in CH_2Cl_2 (20 mL) was added $SOCl_2$ (1.836 g, 15.429 mmol). The resulting mixture was stirred at rt for overnight. The mixture was concentrated under reduced pressure, and the crude was purified by silica gel chromatography (0 to 15% CH_3OH/ CH_2Cl_2) to afford the titled compound as a white solid (2 g, 93%). LC/MS: mass calcd. for $C_{14}H_{12}ClNO_3$: 277.05, found: 278.00 [M+H]+.

Synthesis of 2,4-dihydroxy-5-methylbenzaldehyde

1) $POCl_3$, DMF, MeCN, 0 °C-rt, 3 h
2) H_2O, 50 °C, 30 min

6

To a solution of 4-methylbenzene-1,3-diol (5.0 g, 40.278 mmol) and DMF (4.6 mL, 2.0 eq.) in CH_3CN (70 ml) was added phosphoryl trichloride (6.3 mL, 1.2 eq.) at 0°C. The reaction was stirred at room temperature for 3 hours and the solid was isolated by filtration. The yellow solid was washed with cooled CH_3CN (10 mL), and H_2O (30 mL) was added. The resulting mixture was stirred at 50°C for 30 min and cooled to room temperature, filtered to afford 2,4-

CA 03141003 2021-12-8

dihydroxy-5-methylbenzaldehyde as white solid (4 g, 64%). LC/MS: mass calcd. for $C_8H_8O_3$: 152.05, found: 153.10 [M+H]+.

Synthesis of 4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxy-5-methylbenzaldehyde

3 → 4 (6, $NaHCO_3$, NaI, DMF, 60°C, 3 h)

To a solution of 3-(chloromethyl)-1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)pyridin-2(1*H*)-one (4 g, 14.404 mmol) in DMF (40 mL) was added 2,4-dihydroxy-5-methylbenzaldehyde (2.411 g, 15.844 mmol), $NaHCO_3$ (1.815 g, 21.606 mmol), NaI (1.08 g, 7.202 mmol). The mixture was stirred at 60 °C for 4 h. After cooling to rt, the reaction was quenched with water (100 mL), and extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous sodium sulfate, the solids were removed by filtration and the solvent of the filtrate was removed under reduced pressure. The crude was purified by silica gel chromatography (0 to 15% CH_3OH/CH_2Cl_2) to afford the titled compound as a white solid (3.5 g, 62%). LC/MS: mass calcd. for $C_{22}H_{19}NO_6$: 393.12, found: 394.10 [M+H]+.

Synthesis of 3-((5-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile

4 → 5 (Cs_2CO_3, DMF, rt)

To a solution of 4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxy-5-methylbenzaldehyde (3.5 g, 8.897 mmol) in DMF (35 mL) was added 3-(bromomethyl)benzonitrile (2.093 g, 10.68 mmol), Cs_2CO_3 (4.348 g, 13.346 mmol). The resulting mixture was stirred at rt for overnight. Then the reaction was quenched with water (50 mL). The resulting mixture was extracted with ethyl acetate (3 x 50 mL). The organic

CA 03141003 2021-12-8

layers were combined, dried over anhydrous sodium sulfate, filtered and concentrated. The crude was purified by silica gel chromatography (0 to 15% CH_3OH/ CH_2Cl_2) to afford the titled compound as a white solid (3.0 g, 66%). LC/MS: mass calcd. for $C_{30}H_{24}N_2O_6$: 508.16, found: 509.10 [M+H]+.

Synthesis of (2-((3-cyanobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzyl)-D-serine

To a mixture of 3-((5-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile (508 mg, 1 mmol), D-serine (105 mg, 0.999 mmol) and sodium cyanoborohydride (63 mg, 1.003 mmol) was added acetic acid (5 mL) and DMF (15 mL) respectively. And the mixture was maintained under nitrogen and stirred at 80°C for 3 h. The reaction cooled to rt, and the solvent was removed under reduced pressure. The crude was purified by silica gel chromatography (0 to 20% ethyl acetate/petroleum ether) to afford 400 mg crude product, purified by preparatory HPLC with the following conditions: XBridge Prep OBD C18, 30 × 150 mm, 5 um; mobile phase A: Water (10 mmol/L NH_4HCO_3), mobile phase B: ACN; flow rate: 60 mL/min; Gradient: 40% B to 75% B in 9 min; 220 nm; Rt: 8.99 min. After lyophilization, the titled compound was obtained as white solid (340 mg, 56%). LC/MS: mass calcd. for 597.21, found $C_{33}H_{31}N_3O_8$: 598.20 [M+H]+. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.99 (d, J = 1.8 Hz, 1H), 7.89 (dt, J = 8.0, 1.4 Hz, 1H), 7.81 (dt, J = 7.8, 1.4 Hz, 1H), 7.65 – 7.55 (m, 3H), 7.19 (s, 1H), 7.01 – 6.94 (m, 2H), 6.91 – 6.84 (m, 2H), 6.35 (t, J = 6.8 Hz, 1H), 5.29 – 5.17 (m, 2H), 4.98 (s, 2H), 4.30 (s, 4H), 3.95-4.08 (m, 2H), 3.75 (dd, J = 11.3, 4.5 Hz, 1H), 3.64 (dd, J = 11.3, 6.8 Hz, 1H), 3.19 – 3.13 (m, 1H), 2.15 (s, 3H).

Synthesis of (2*R*,4*R*)-1-(2-((3-cyanobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzyl)-4-hydroxypyrrolidine-2-carboxylic acid

CA 03141003 2021-12-8

8

The titled compound was prepared according to the method to prepare 7. The crude was purified by silica gel chromatography (0 to 20% ethyl acetate/petroleum ether) then by preparatory HPLC with the following conditions: Column: XBridge Prep OBD C18 Column,
5 30×150 mm, 5□m; Mobile Phase A:Water (10 mmol/L NH_4HCO_3), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 40% B to 75% B in 9 min; 220 nm; Rt: 8.99 min. After lyophilization, the titled compound was obtained as white solid (232.3 mg, 37%). LC/MS: mass calcd. for 623.23, found $C_{35}H_{33}N_3O_8$: 624.3 [M+H]+. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.95 (d, J = 2.0 Hz, 1H), 7.91 – 7.84 (m, 1H), 7.81 (dt, J = 7.8, 1.4 Hz, 1H), 7.66 – 7.55 (m, 3H), 7.16 (s,
10 1H), 6.98 (dd, J = 5.5, 3.0 Hz, 2H), 6.91 – 6.84 (m, 2H), 6.35 (t, J = 6.8 Hz, 1H), 5.30 – 5.18 (m, 2H), 4.97 (s, 2H), 4.30 (s, 4H), 4.20 (s, 1H), 4.06 (d, J = 13.0 Hz, 1H), 3.91 (d, J = 12.9 Hz, 1H), 3.48 (dd, J = 10.0, 4.5 Hz, 1H), 2.99 (d, J = 10.9 Hz, 1H), 2.84 (dd, J = 10.9, 4.6 Hz, 1H), 2.34 – 2.26 (m, 1H), 2.14 (s, 3H), 1.90 (d, J = 13.2 Hz, 1H).

Synthesis of (*R*)-2-((2-((3-cyanobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-
15 **oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzyl)amino)-3-hydroxy-2-methylpropanoic acid**

9

The titled compound was made according to the procedure to make compound 7, and was purified by reverse phase C18 column (0-60% H_2O (0.5% TFA)/ACN) to afford the titled
20 compound as a white solid (140 mg, 29%). LC/MS: mass calcd. for $C_{34}H_{33}N_3O_8$: 611.23, found:

CA 03141003 2021-12-8

612.3 [M+H]+. ^{1}H NMR (300 MHz, DMSO-d_6) δ 7.96 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.65 – 7.52 (m, 3H), 7.24 (s, 1H), 7.01 – 6.92 (m, 2H), 6.91 – 6.78 (m, 2H), 6.34 (t, J = 6.8 Hz, 1H), 5.22 (s, 2H), 4.98 (s, 2H), 4.29 (s, 4H), 4.01 (s, 2H), 3.67 (d, J = 11.4 Hz, 2H), 3.63 – 3.48 (m, 2H), 2.15 (s, 3H), 1.28 (s, 3H).

5

Synthesis of (2-((3-cyanobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzyl)-L-serine

HO O N H OH O O O N O O CN

10

The titled compound was made according to the procedure to make compound 7, and was

10 purified by reverse phase C18 column (0 to 60% H_2O (0.5% TFA)/ACN) to afford the titled compound as a white solid (140 mg, 29%). LC/MS: mass calcd. for 597.21, found $C_{33}H_{31}N_3O_8$: 598.2 [M+H]+. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.99 (d, J = 1.8 Hz, 1H), 7.89 (dt, J = 8.0, 1.4 Hz, 1H), 7.81 (dt, J = 7.8, 1.4 Hz, 1H), 7.65 – 7.55 (m, 3H), 7.19 (s, 1H), 7.01 – 6.94 (m, 2H), 6.91 – 6.84 (m, 2H), 6.35 (t, J = 6.8 Hz, 1H), 5.29 – 5.17 (m, 2H), 4.98 (s, 2H), 4.30 (s, 4H),

15 3.95-4.08 (m, 2H), 3.75 (dd, J = 11.3, 4.5 Hz, 1H), 3.64 (dd, J = 11.3, 6.8 Hz, 1H), 3.19 – 3.13 (m, 1H), 2.15 (s, 3H).

Synthesis of 2-((3-chlorobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzaldehyde

CA 03141003 2021-12-8

100

Compound **100** was made using a procedure analogous to the procedure to prepare compound **5**.

5 **Synthesis of (2-((3-chlorobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methylbenzyl)-D-serine**

100 → ($NaBH_3CN$, AcOH; DMF, 80 °C) → 101

To a mixture of 3-((5-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile (480 mg, 0.927
10 mmol) and D-serine (389.5 mg, 3.707 mmol) in DMF (5 mL) was added acetic acid (5.5 mg, 0.093 mmol) and the mixture was stirred at rt for 30 min. Then $NaCNBH_3$ (204 mg, 3.244 mmol) was added and the mixture was heated at 80°C for 3 h. The reaction was then cooled to rt. The mixture was dropwise added in water at 0°C, The crude obtained was purified by reverse phase C18 column (0 to 60% H_2O (0.5% TFA)/ACN) to afford the titled compound as a white solid
15 (46.7 mg, 8%). LC/MS: mass calcd. for $C_{32}H_{31}ClN_2O_8$: 607.18, found: 607.2[M+H]+. ^{1}H NMR (300 MHz, DMSO-d_6) δ 7.64-7.55 (m, 3H), 7.52 – 7.43 (m, 1H), 7.43 – 7.30 (m, 2H), 7.24 (s, 1H), 7.02 – 6.92 (m, 2H), 6.91 – 6.81 (m, 2H), 6.34 (t, J = 6.8 Hz, 1H), 5.24 – 5.09 (m, 2H), 4.98 (s, 2H), 4.29 (s, 4H), 3.95-4.10 (m, 2H), 3.83-3.60 (m, 3H), 2.13 (s, 3H).

CA 03141003 2021-12-8

Synthesis of 4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methyl-2-(pyridin-3-ylmethoxy)benzaldehyde

4 → (Cs_2CO_3, DMF, rt; 3-(bromomethyl)pyridine) **102**

5 To a solution of 4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxy-5-methylbenzaldehyde (500 mg, 1.271 mmol, 1.0 eq.) in DMF (5 mL) was added 3-(bromomethyl)pyridine (262 mg, 1.525 mmol), Cs_2CO_3 (621 mg, 1.907 mmol). The resulting mixture was stirred at rt for overnight. The resulting mixture was dropwise added into 40 mL ice water, The suspension was filtered and washed with DMF to
10 afford the titled compound as a white solid (500 mg, 81%). LC/MS: mass calcd. for $C_{28}H_{24}N_2O_6$: 484.5, found: 485.3 [M+H]+.

Synthesis of (4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methyl-2-(pyridin-3-ylmethoxy)benzyl)-D-serine

15 **103**

To a mixture of 4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-5-methyl-2-(pyridin-3-ylmethoxy)benzaldehyde (500 mg,1.032 mmol, 1 eq) and D-Serine (433.8 mg, 4.128 mmol, 4 eq) in DMF (5 mL) was added acetic acid (6 mg, 0.103 mmol) and the mixture was stirred at rt for 30 min. Then $NaCNBH_3$ (227 mg, 3.612 mmol) was added
20 and the mixture was heated at 80°C for 3 h. The reaction was then cooled to rt, then dropwise added into water at 0°C. The solid obtained was purified by a reverse phase C18 column (0 to 60% H_2O (0.5%TFA)/ CH_3CN) to afford the titled compound as a white solid (159 mg, 33%). LC/MS: mass calcd. for $C_{31}H_{31}N_3O_8$: 573.21, found: 574.3[M+H]+. ^1H NMR (300 MHz,

CA 03141003 2021-12-8

DMSO-d_6) δ 8.71 (d, J = 2.2 Hz, 1H), 8.54 (dd, J = 4.8, 1.6 Hz, 1H), 8.03 – 7.93 (m, 1H), 7.62 (dt, J = 6.7, 3.0 Hz, 2H), 7.41 (dd, J = 7.8, 4.8 Hz, 1H), 7.18 (s, 1H), 7.02 – 6.93 (m, 2H), 6.93 – 6.84 (m, 2H), 6.35 (t, J = 6.8 Hz, 1H), 5.29 – 5.14 (m, 2H), 4.99 (s, 2H), 4.30 (s, 4H), 4.02-3.97 (m, 2H), 3.78-3.58 (m, 3H), 3.16 (d, J = 6.0 Hz, 2H), 2.15 (s, 3H).

5

Synthesis of 5-chloro-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxybenzaldehyde

3 → ($NaHCO_3$, NaI, DMF, 60°C, 3 h) → 200

To a solution of 3-(chloromethyl)-1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)pyridin-2(1*H*)-
10 one (500 mg, 1.800 mmol, 1.0 eq.) in DMF (5 mL) was added 5-chloro-2,4-dihydroxybenzaldehyde (373 mg, 2.161 mmol, 1.2 eq.), Na_2CO_3 (227 mg, 2.701 mmol), NaI (135 mg, 0.90 mmol). The resulting mixture was stirred at 60 °C for 3 h. After cooling to rt, the mixture was dropwise added into 40 mL ice water, The suspension was filtered and washed with CH_3OH to afford the 5-chloro-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-
15 dihydropyridin-3-yl)methoxy)-2-hydroxybenzaldehyde as a white solid (500 mg, 67%). LC/MS: mass calcd. for $C_{21}H_{16}ClNO_6$: 413.81, found: 414.1 [M+H]+.

Synthesis of 3-((4-chloro-5-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formylphenoxy)methyl)benzonitrile

200 → (Cs_2CO_3, DMF, rt) → 201

20 To a solution of 5-chloro-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxybenzaldehyde (500 mg, 1.208 mmol) in DMF (5 mL) was added 3-(bromomethyl)benzonitrile (284 mg, 1.450 mmol), Cs_2CO_3 (590.5 mg, 1.812 mmol,

CA 03141003 2021-12-8

1.5 eq.). The resulting mixture was stirred at rt for overnight. The resulting mixture was dropwise added into ice water (40 mL), the suspension was filtered and washed with CH_3OH to afford the titled compound as a white solid (400 mg, 63 %). LC/MS: mass calcd. for $C_{29}H_{21}ClN_2O_6$: 528.94, found: 529.3 [M+H]+.

5

Synthesis of (5-chloro-2-((3-cyanobenzyl)oxy)-4-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzyl)-D-serine

201 → (D-serine, $NaBH_3CN$, AcOH, DMF, 80 °C) → 202

To a mixture of 3-((4-chloro-5-((1-(2,3-dihydrobenzo[*b*][1,4]dioxin-6-yl)-2-oxo-1,2-
10 dihydropyridin-3-yl)methoxy)-2-formylphenoxy)methyl)benzonitrile (400 mg, 0.756 mmol) and D-Serine (318 mg, 3.025 mmol) in DMF (5 mL) was added acetic acid (4.5 mg, 0.076 mmol) and the mixture was stirred at rt for 30 min. Then $NaCNBH_3$ (166 mg, 2.65 mmol) was added and the mixture was heated to 80°C for 3 h. The reaction was cooled to rt, and the mixture was added dropwise into water at 0°C, The crude was purified by reverse phase column
15 chromatography (C18 column, 0 to 60% H_2O (0.5% TFA)/CH_3CN) to afford the titled compound as a white solid (159 mg, 33%). LC/MS: mass calcd. for $C_{32}H_{28}ClN_3O_8$: 617.16, found: 618.2[M+H]+. ^1H NMR (300 MHz, DMSO-d_6) δ 7.95 (d, J = 1.7 Hz, 1H), 7.90 – 7.77 (m, 2H), 7.77 – 7.54 (m, 3H), 7.50 (s, 1H), 7.05 (s, 1H), 6.97 (dd, J = 5.5, 3.1 Hz, 2H), 6.87 (dd, J = 8.6, 2.5 Hz, 1H), 6.36 (t, J = 6.8 Hz, 1H), 5.33 – 5.17 (m, 2H), 5.05 (s, 2H), 4.28 (s, 4H), 3.96
20 (s, 2H), 3.60-3.76 (m, 4H), 3.18 (t, J = 5.4 Hz, 1H).

Synthesis of (S)-3-((4-chloro-5-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)phenoxy)methyl)benzonitrile

CA 03141003 2021-12-8

201 → (NaBH$_3$CN, AcOH; DMF, 80 °C) → 205

To a mixture of 3-((4-chloro-5-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formylphenoxy)methyl)benzonitrile (400 mg, 0.756 mmol, 1 eq) and (S)-5-AMINOMETHYL-PYRROLIDIN-2-ONE (345 mg, 3.025 mmol, 4 eq) in DMF (5 ml) was added acetic acid (4.5 mg, 0.076 mmol) and the mixture was stirred at rt for 30 min. Then NaCNBH$_3$ (166 mg, 2.65 mmol) was added and the mixture was heated at 80°C for 3 h. The reaction was then cooled to rt. The mixture was dropwise added in water at 0°C. The precipitate was filtered and purified by reverse phase column chromatography (C18 column, 0 to 60% H_2O (0.5% TFA)/CH_3CN). After lyophilization, the titled compound was afforded as a white solid (78.2 mg, 13% yield). LC/MS: mass calcd. for $C_{34}H_{31}ClN_4O_6$: 627.086, found: 627.20 [M+H]+. 1H NMR (300 MHz, DMSO-d6) d (ppm): 8.47 - 8.89 (m, 2H), 7.93 (s, 1H), 7.74 - 7.91 (m, 2H), 7.41 - 7.74 (m, 5H), 7.21 (s, 1H), 6.91 - 6.99 (m, 2H), 6.31 - 6.42 (m, 1H), 5.27 (s, 2H), 5.09 (s, 2H), 4.29 (s, 4H), 4.17 (s, 2H), 3.75 - 3.91 (m, 1H), 2.83 - 3.09 (m, 2H), 2.05 - 2.21 (m, 3H), 1.68 - 1.79 (m, 1H)

The following compounds were synthesized using an analogous procedure as in the preparation of compound 202.

#	STRUCTURE	Exact Mass	LC-MS (M+H)	^{1}H NMR
203	203	611.23	612.2	^{1}H NMR (300 MHz, DMSO-d_6) δ 7.96 (s, 1H), 7.83 (dd, J = 24.0, 9.0 Hz, 4H), 7.65 – 7.52 (m, 3H), 7.18 (d,

CA 03141003 2021-12-8

#	STRUCTURE	Exact Mass	LC-MS (M+H)	^{1}H NMR
				J = 3.5 Hz, 1H), 6.99 – 6.88 (m, 2H), 6.88 – 6.78 (m, 2H), 6.33 (t, J = 6.9 Hz, 1H), 5.20 (d, J = 4.0 Hz, 3H), 4.95 (s, 1H), 4.27 (s, 4H), 4.11 – 3.94 (m, 2H), 3.73 (dd, J = 11.3, 4.6 Hz, 1H), 3.62 (dd, J = 11.3, 6.7 Hz, 2H), 3.16 (d, J = 6.9 Hz, 1H), 2.54 (dd, J = 7.5, 2.5 Hz, 3H), 1.11 (td, J = 7.5, 2.9 Hz, 3H)
204	HO O N O O O O N H OH O CN **204**	625.24	624.3 (M-H)	^{1}H NMR (300 MHz, DMSO-d_6) δ 7.96 (s, 1H), 7.91 – 7.70 (m, 3H), 7.58 (dd, J = 9.2, 6.6 Hz, 3H), 7.25 (d, J = 3.9 Hz, 1H), 6.99 – 6.91

CA 03141003 2021-12-8

#	STRUCTURE	Exact Mass	LC-MS (M+H)	^{1}H NMR
				(m, 2H), 6.83 (td, J = 7.7, 6.9, 3.9 Hz, 2H), 6.33 (t, J = 6.8 Hz, 1H), 5.20 (d, J = 3.1 Hz, 2H), 4.95 (s, 2H), 4.27 (s, 4H), 4.13 – 3.96 (m, 2H), 3.73 (dd, J = 11.2, 4.5 Hz, 1H), 3.63 (dd, J = 11.4, 6.6 Hz, 2H), 3.21 (td, J = 13.8, 6.7 Hz, 3H), 1.14 (dd, J = 7.0, 3.2 Hz, 6H).

The following compounds were prepared using a procedure analogous to those described in the preparation of compound 10.

CA 03141003 2021-12-8

#	STRUCTURE	Exact Mass	LC-MS (M+H)	^{1}H NMR
11		581.62	582.2	^{1}H NMR (300 MHz, DMSO-d_6) δ 8.98 (s, 1H), 7.95 (t, J = 1.7 Hz, 1H), 7.87 – 7.75 (m, 2H), 7.65 – 7.53 (m, 3H), 7.22 (s, 1H), 7.00 – 6.90 (m, 2H), 6.90 – 6.79 (m, 2H), 6.33 (t, J = 6.8 Hz, 1H), 5.29 – 5.14 (m, 2H), 4.98 (s, 2H), 4.27 (s, 4H), 4.11 (s, 2H), 3.97 – 3.86 (m, 1H), 2.14 (s, 3H), 1.42 (d, J = 7.1 Hz, 3H).
12		611.64	612.2	^{1}H NMR (300 MHz, DMSO-d_6) δ 7.91 (d, J = 1.9 Hz, 1H), 7.89 – 7.73 (m, 3H), 7.58 (t, J = 7.7 Hz, 2H), 7.13 (s, 1H), 6.95 (dd, J = 5.5, 3.1 Hz, 2H), 6.89 – 6.77 (m, 2H), 6.33 (t, J = 6.8 Hz, 1H), 5.18 (s, 2H), 4.94 (s, 2H), 4.28 (s, 4H), 3.99 – 3.74 (m, 4H), 2.80 (d, J = 7.2 Hz, 2H), 2.43 (s, 3H), 2.12 (s, J = 2.5 Hz, 3H).

CA 03141003 2021-12-8

Synthesis of 5-((4-chloro-5-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-formylphenoxy)methyl)nicotinonitrile

200 → (5-(chloromethyl)nicotinonitrile; Cs_2CO_3, DMF, rt) → 206

5 To a solution of 5-(chloromethyl)nicotinonitrile (350mg, 2.3 mmol) in DMF (4 mL) was added 5-chloro-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxybenzaldehyde (790 mg, 1.9 mmol), Cesium carbonate (935 mg, 2.9 mmol). The resulting mixture was stirred at rt for overnight. The resulting mixture was dropwise added into 30 mL ice water. The suspension was filtered and washed with MeOH to afford the titled
10 compound as white solid (340 mg,34.5% yield) LC/MS: mass calcd. for $C_{28}H_{20}ClN_3O_6$: 529.928, found: 530.40 [M+H]+.

Synthesis of (5-chloro-2-((5-cyanopyridin-3-yl)methoxy)-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzyl)-D-serine

15

206 → (D-serine; $NaBH_3CN$, AcOH; DMF, 80 °C) → 207

To a mixture of 5-((4-chloro-5-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-
20 dihydropyridin-3-yl)methoxy)-2-formylphenoxy)methyl)nicotinonitrile (300 mg, 0.57 mmol) and D-Serine (240 mg, 2.3 mmol) in DMF (4 mL) was added acetic acid (3.4 mg, 0.057 mmol)

CA 03141003 2021-12-8

and the mixture was stirred at rt for 30 min. Then $NaCNBH_3$ (125 mg, 2 mmol) was added and the mixture was heated to 80°C for 3 h. The reaction was cooled to rt, and the mixture was added dropwise into water at 0°C. The precipitate was filtered and purified by reverse phase column chromatography (C18 column, 0 to 60% H_2O (0.5% TFA)/CH_3CN) to afford the titled
5 compound as a white solid (54 mg, 15%). LC/MS: mass calcd. for $C_{31}H_{27}ClN_4O_8$: 618.021, found: 619.10 [M+H]+. ^1H NMR (300 MHz, DMSO-d6) d (ppm): 9.01 - 9.05 (m, 1H), 8.96 - 8.99 (m, 1H), 8.39 - 8.46 (m, 1H), 7.65 - 7.71 (m, 2H), 7.59 (s, 1H), 7.12 (s, 1H), 6.91 - 7.01 (m, 2H), 6.82 - 6.91 (m, 1H), 6.38 (t, J = 6.9 Hz, 1H), 5.51 - 6.62 (m, 1H), 5.30 (s, 2H), 5.11 (s, 2H), 4.14 - 4.55 (m, 6H), 3.91 (s, 1H), 3.85 (s, 2H).

10

Synthesis of 2-((5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)methoxy)-5-chloro-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzaldehyde

200 → (PPh3, DIAD, DCM, rt) → 208

CA 03141003 2021-12-8

To a mixture of (5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)methanol [1646287-85-5] (180 mg, 1 mmol), 5-chloro-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-2-hydroxybenzaldehyde (422, 1 mmol) and triphenylphosphine (400 mg, 1.5 mmol,) in DCM (4 ml) was added diisopropyl azodicarboxylate (310 mg, 1.5 mmol) at 0°C under N2. The mixture was stirred at rt for 18 hours. The mixture was concentrated under reduced pressure. The residue obtained was purified by reverse C18 column (0-60% H2O (0.5%TFA)/ACN) to afford titled compound as white solid (150 mg, 26% yield). LC/MS: mass calcd. for $C_{29}H_{22}ClN_5O_6$: 571.968, found: 572.25[M+H]+.

Synthesis of ((2-((5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)methoxy)-5-chloro-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzyl)-D-serine

208 → 209 (D-serine, $NaBH_3CN$, AcOH; DMF, 80 °C)

To a mixture of 2-((5-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)methoxy)-5-chloro-4-((1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-oxo-1,2-dihydropyridin-3-yl)methoxy)benzaldehyde (150 mg, 0.26 mmol) and D-Serine (110 mg, 1 mmol) in DMF (4 ml) was added acetic acid l (1.6 mg, 0.026 mmol) and the mixture was stirred at rt for 30 min. Then $NaCNBH_3$ (60 mg, 0.9 mmol) was added and the mixture was heated at 80°C for 3 h. The reaction was then cooled to rt. The mixture was dropwise added in water at 0°C. The precipitate was filtered and then purified by reverse phase column chromatography (C18 column, 0 to 60% H_2O (0.5% TFA)/CH_3CN). After lyophilization, the titled compound was afforded as a white solid (28.6 mg, 16% yield) LC/MS: mass calcd. for $C_{32}H_{29}ClN_6O_8$: 660.17, found: 661.15 [M+H]+. ^1H NMR (300 MHz, DMSO-d6) d (ppm): 9.41 (s, 1H), 9.15 - 9.21 (m, 1H), 8.72 - 8.76 (m, 1H), 8.60 - 8.66 (m, 1H), 8.00 (s, 1H), 7.58 - 7.68 (m, 2H), 7.54 (s, 1H), 7.12 (s, 1H),6.91 - 7.01 (m, 2H), 6.83 - 6.91 (m,

CA 03141003 2021-12-8

1H), 6.34 (t, J = 6.8 Hz, 1H), 5.33 (s, 2H), 5.08 (s, 2H), 4.26 (s, 4H), 3.89 - 4.08 (m, 3H), 3.03 - 3.13 (m, 2H).

5

Experimental Examples

Example 1. HBV core plasmid & HBV pol plasmid

A schematic representation of the pDK-pol and pDK-core vectors is shown in Fig. 1A and 1B, respectively. An HBV core or pol antigen optimized expression cassette containing a
10 CMV promoter (SEQ ID NO: 18), a splicing enhancer (triple composite sequence) (SEQ ID NO: 10), Cystatin S precursor signal peptide SPCS (NP_0018901.1) (SEQ ID NO: 9), and pol (SEQ ID NO: 5) or core (SEQ ID NO: 2) gene was introduced into a pDK plasmid backbone, using standard molecular biology techniques.

The plasmids were tested *in vitro* for core and pol antigen expression by Western blot
15 analysis using core and pol specific antibodies, and were shown to provide consistent expression profile for cellular and secreted core and pol antigens (data not shown).

Example 2. Generation of Adenoviral Vectors Expressing a Fusion of Truncated HBV Core Antigen with HBV Pol Antigen

20 The creation of an adenovirus vector has been designed as a fusion protein expressed from a single open reading frame. Additional configurations for the expression of the two proteins, e.g. using two separate expression cassettes, or using a 2A-like sequence to separate the two sequences, can also be envisaged.

25 <u>Design of expression cassettes for adenoviral vectors</u>

The expression cassettes (diagrammed in FIG. 2A and FIG. 2B) are comprised of the CMV promoter (SEQ ID NO: 19), an intron (SEQ ID NO:12) (a fragment derived from the human ApoAI gene - GenBank accession X01038 base pairs 295 – 523, harboring the ApoAI second intron), followed by the optimized coding sequence – either core alone or the core and
30 polymerase fusion protein preceded by a human immunoglobulin secretion signal coding sequence (SEQ ID NO: 14), and followed by the SV40 polyadenylation signal (SEQ ID NO: 13).

CA 03141003 2021-12-8

A secretion signal was included because of past experience showing improvement in the manufacturability of some adenoviral vectors harboring secreted transgenes, without influencing the elicited T-cell response (mouse experiments).

The last two residues of the Core protein (VV) and the first two residues of the Polymerase protein (MP) if fused results in a junction sequence (VVMP) that is present on the human dopamine receptor protein (D3 isoform), along with flanking homologies.

The interjection of an AGAG linker between the core and the polymerase sequences eliminates this homology and returned no further hits in a Blast of the human proteome.

Example 3. *In Vivo* Immunogenicity Study of DNA Vaccine in Mice

An immunotherapeutic DNA vaccine containing DNA plasmids encoding an HBV core antigen or HBV polymerase antigen was tested in mice. The purpose of the study was designed to detect T-cell responses induced by the vaccine after intramuscular delivery via electroporation into BALB/c mice. Initial immunogenicity studies focused on determining the cellular immune responses that would be elicited by the introduced HBV antigens.

In particular, the plasmids tested included a pDK-Pol plasmid and pDK-Core plasmid, as shown in FIGS. 1A and 1B, respectively, and as described above in Example 1. The pDK-Pol plasmid encoded a polymerase antigen having the amino acid sequence of SEQ ID NO: 7, and the pDK-Core plasmid encoding a Core antigen having the amino acid sequence of SEQ ID NO: 2. First, T-cell responses induced by each plasmid individually were tested. The DNA plasmid (pDNA) vaccine was intramuscularly delivered via electroporation to Balb/c mice using a commercially available TriGrid™ delivery system-intramuscular (TDS-IM) adapted for application in the mouse model in cranialis tibialis. See International Patent Application Publication WO2017172838, and U.S. Patent Application No. 62/607,430, entitled "Method and Apparatus for the Delivery of Hepatitis B Virus (HBV) Vaccines," filed on December 19, 2017 for additional description on methods and devices for intramuscular delivery of DNA to mice by electroporation, the disclosures of which are hereby incorporated by reference in their entireties. In particular, the TDS-IM array of a TDS-IM v1.0 device having an electrode array with a 2.5 mm spacing between the electrodes and an electrode diameter of 0.030 inch was inserted percutaneously into the selected muscle, with a conductive length of 3.2 mm and an effective penetration depth of 3.2 mm, and with the major axis of the diamond configuration of the

electrodes oriented in parallel with the muscle fibers. Following electrode insertion, the injection was initiated to distribute DNA (e.g., 0.020 ml) in the muscle. Following completion of the IM injection, a 250 V/cm electrical field (applied voltage of 59.4 -65.6 V, applied current limits of less than 4 A, 0.16 A/sec) was locally applied for a total duration of about 400 ms at a 10% duty
5 cycle (i.e., voltage is actively applied for a total of about 40 ms of the about 400 ms duration) with 6 total pulses. Once the electroporation procedure was completed, the TriGridTM array was removed and the animals were recovered. High-dose (20 µg) administration to BALB/c mice was performed as summarized in Table 1. Six mice were administered plasmid DNA encoding the HBV core antigen (pDK-core; Group 1), six mice were administered plasmid DNA encoding
10 the HBV pol antigen (pDK-pol; Group 2), and two mice received empty vector as the negative control. Animals received two DNA immunizations two weeks apart and splenocytes were collected one week after the last immunization.

Table 1: Mouse immunization experimental design of the pilot study.

Group	N	pDNA	Unilateral Admin Site (alternate sides)	Dose	Vol	Admin Days	Endpoint (spleen harvest) Day
1	6	Core	CT + EP	20 µg	20 µL	0, 14	21
2	6	Pol	CT + EP	20 µg	20 µL	0, 14	21
3	2	Empty Vector (neg control)	CT + EP	20 µg	20 µL	0, 14	21

15 CT, cranialis tibialis muscle; EP, electroporation.

Antigen-specific responses were analyzed and quantified by IFN-γ enzyme-linked immunospot (ELISPOT). In this assay, isolated splenocytes of immunized animals were incubated overnight with peptide pools covering the Core protein, the Pol protein, or the small
20 peptide leader and junction sequence (2µg/ml of each peptide). These pools consisted of 15 mer peptides that overlap by 11 residues matching the Genotypes BCD consensus sequence of the Core and Pol vaccine vectors. The large 94 kDan HBV Pol protein was split in the middle into two peptide pools. Antigen-specific T cells were stimulated with the homologous peptide pools and IFN-γ-positive T cells were assessed using the ELISPOT assay. IFN-γ release by a single

CA 03141003 2021-12-8

antigen-specific T cell was visualized by appropriate antibodies and subsequent chromogenic detection as a colored spot on the microplate referred to as spot-forming cell (SFC).

Substantial T-cell responses against HBV Core were achieved in mice immunized with the DNA vaccine plasmid pDK-Core (Group 1) reaching 1,000 SFCs per 10^6 cells (FIG. 3). Pol
5 T-cell responses towards the Pol 1 peptide pool were strong (~1,000 SFCs per 10^6 cells). The weak Pol-2-directed anti-Pol cellular responses were likely due to the limited MHC diversity in mice, a phenomenon called T-cell immunodominance defined as unequal recognition of different epitopes from one antigen. A confirmatory study was performed confirming the results obtained in this study (data not shown).

10 The above results demonstrate that vaccination with a DNA plasmid vaccine encoding HBV antigens induces cellular immune responses against the administered HBV antigens in mice. Similar results were also obtained with non-human primates (data not shown).

Example 4. PD-1/PD-L1 Biochemical Protein-Protein Interaction

15 Compounds were tested in protein-protein interaction assay to determine if they can specifically block the interaction between the extracellular domains of PD-1/PD-L1. Binding of the protein pairs is measured using a bead based amplified luminescent proximity homogeneous assay (ALPHA) platform. Binding of each protein pair results in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal. Assays are performed in 50 mM
20 Tris (pH 7.4), 0.0015% Triton X-100, 0.1% BSA. Final protein concentration in the assays were 5 nM (His tagged PD-L1), 5 nM (biotinylated PD-1), 10 µg/ml ALPHA assay acceptor beads, 10 µg/ml ALPHA assay donor beads. After an assay reaction time of 2 hours at 25°C, binding was measured. The specificity of the binding was determined by testing the compounds in an assay with an irrelevant protein that is both His tagged and biotinylated. The final protein
25 concentration used in the assay was 5 nM, 10 µg/ml ALPHA assay acceptor beads, 10 µg/ml ALPHA assay donor beads. After an assay reaction time of 2 hours at 25°C, binding was measured. IC_{50} values were calculated from the fit of the dose-response curves to a four-parameter equation.

The specificity of the binding was determined by testing the compounds in an assay with
30 an irrelevant protein that is both His tagged and biotinylated (ErbB3/her3). The final protein concentration used in the assay was 5 nM, 10 µg/mL ALPHA assay acceptor beads, 10 µg/mL

CA 03141003 2021-12-8

ALPHA assay donor beads. After an assay reaction time of 2 hours at 25°C, binding was measured. IC_{50} values were calculated from the fit of the dose-response curves to a four-parameter equation. Compounds were specific if they show $EC_{50} > 25$ µM in this assay or that the stimulation index compared to the PD-1/PD-L1 interaction was greater than three.

5

Table 2a. Compound Activity

Compound Number	ALPHA-LISA IC_{50} (µM)
7	1.1
8	3.4
9	1.2
10	1.2
11	3.9
12	1.6
101	3.0
103	1.0
202	0.3
203	2.7
204	3.6

10 **Table 2b. Compound Activity**

Compound Number	ALPHA-LISA IC_{50} (µM)
205	0.36
207	0.32

CA 03141003 2021-12-8

Compound Number	**ALPHA-LISA IC_{50} (μM)**
209	0.55

Example 5. PD-1/PD-L1 NFAT Reporter Assay

Compounds were tested in functional co-culture reporter assay in which TCR-mediated NFAT activity is inhibited by the engagement of PD-1 with PD-L1. Blocking the PD-1/PD-L1 interaction impairs PD-1 mediated blunting of TCR signaling and significantly increase NFAT-mediated transcription of luciferase. CHO cells expressing surface-bound anti-CD3 antibodies and PD-L1 (artificial antigen-presenting cells, aAPC-PD-L1) were mixed with Jurkat cells overexpressing PD-1 and expressing a luciferase construct under NFAT control in RPMU assay medium with 1% FBS and immediately seeded on plates containing the compounds. The co-culture is then incubated for 20 hours at 37°C, 5% CO_2. Luciferase activity is assessed by adding the Bio-Glo reagent and measuring luminescence with a plate reader. Data are reported as least effective concentrations (LEC). LEC values are calculated from the fit of the dose response curves to the mean of the cell control plus three times the standard deviation.

It is understood that the examples and embodiments described herein are for illustrative purposes only, and that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the invention as defined by the appended claims.

CA 03141003 2021-12-8

CLAIMS

It is claimed:

1. A therapeutic combination for use in treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising:

5 i) at least one of:

a) a truncated HBV core antigen consisting of an amino acid sequence that is at least 95% identical to SEQ ID NO: 2,

b) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding the truncated HBV core antigen,

10 c) an HBV polymerase antigen having an amino acid sequence that is at least 90% identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity, and

d) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding the HBV polymerase antigen; and

15 ii) a compound of formula (I):

(I)

wherein R^1 is a ring optionally substituted with one or more substituents selected from halogen, CN, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-6}cycloalkyl, C_{1-6}heteroalkyl, NR^xR^y, $NR^xC(=O)R^y$, $NR^xCO_2R^y$,
20 $NR^xC(=O)NR^xR^y$, $OC(=O)NR^xR^y$, O-(6 to 10-membered aryl), O-(5 to 10-membered heteroaryl), and a ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H, halogen, C_{1-4}alkyl and C_{1-4}alkyl substituted with one or more F;

CA 03141003 2021-12-8

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-6}alkyl and C_{1-6}heteroalkyl being optionally substituted with one or more substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, C_{3-6}heterocycle, aryl and heteroaryl;

wherein C_{3-6}heterocycle is optionally substituted with one or more substituent selected from oxo, OH and CO_2H;

with the proviso that R^8 and R^9 are not both H;

or wherein R^8 and R^9 are connected together to form a C_{3-6}heterocycle optionally substituted with one or more substituents selected from C_{1-6}alkyl, oxo, OH and CO_2H;

R^{10} is selected from H, CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, C(=O)NR^xR^y, SO_2-C_{1-6}alkyl, aryl and heteroaryl;

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, C(=O)NR^xR^y and SO_2-C_{1-6}alkyl;

X is N or CR^{12};

R^{12} is selected from H, F, Cl, CN, C(=O)NR^xR^y, aryl and heteroaryl,

wherein aryl and heteroaryl are optionally substituted with one or more substituents selected from CN, halogen, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkyl-CO_2H, C_{1-6}alkyl-CO_2-C_{1-6}alkyl, C_{1-6}alkyl-C(O)NH_2, C_{1-6}alkyl-CO-NHC_{1-6}alkyl, C_{1-6}alkyl-C(O)N(C_{1-6}alkyl)$_2$, C(=O)NR^xR^y and SO_2-C_{1-6}alkyl; and

R^x and R^y are independently selected from H and C_{1-6}alkyl;

or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.

2. The therapeutic combination of claim 1, comprising at least one of the HBV polymerase antigen and the truncated HBV core antigen.
3. The therapeutic combination of claim 2, comprising the HBV polymerase antigen and the truncated HBV core antigen.
4. The therapeutic combination of claim 1, comprising at least one of the first non-naturally occurring nucleic acid molecule comprising the first polynucleotide sequence encoding the truncated HBV core antigen and the second non-naturally occurring nucleic acid

CA 03141003 2021-12-8

molecule comprising the second polynucleotide sequence encoding the HBV polymerase antigen.

5. A therapeutic combination for use in treating a hepatitis B virus (HBV) infection in a subject in need thereof, comprising

5 i) a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 95% identical to SEQ ID NO: 2; and

ii) a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding an HBV polymerase antigen having an amino 10 acid sequence that is at least 90% identical to SEQ ID NO: 7, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; and

iii) a compound of formula (I):

15 (I)

or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein:

R^1 is an optionally substituted monocyclic or bicyclic ring;

R^2, R^3, R^4, R^5, R^6, R^7 and R^{11} are independently selected from H and C_{1-4}alkyl;

R^8 and R^9 are independently selected from H, C_{1-6}alkyl and C_{1-6}heteroalkyl, each of C_{1-} 20 $_{6}$alkyl and C_{1-6}heteroalkyl being optionally substituted with one, two, or three substituents selected from C_{1-4}alkyl, OH, OCH_3, $-CO_2H$, $-CO_2C_{1-4}$alkyl, aryl and heteroaryl;

R^{10} is selected from H and CN;

R^{12} is selected from H, Cl, and CN; and

X is N.

CA 03141003 2021-12-8

6. The therapeutic combination of claim 4 or 5, wherein the first non-naturally occurring nucleic acid molecule further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the truncated HBV core antigen, and the second non-naturally occurring nucleic acid molecule further comprises a polynucleotide sequence encoding a signal sequence operably linked to the N-terminus of the HBV polymerase antigen, preferably, the signal sequence independently comprises the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 15, preferably the signal sequence is independently encoded by the polynucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 14.
7. The therapeutic combination of any one of claims 1-6, wherein
   a) the truncated HBV core antigen consists of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; and
   b) the HBV polymerase antigen comprises the amino acid sequence of SEQ ID NO: 7.
8. The therapeutic combination of any one of claims 1-7, wherein each of the first, and second non-naturally occurring nucleic acid molecules is a DNA molecule, preferably the DNA molecule is present on a plasmid or a viral vector.
9. The therapeutic combination of any one of claims 4 to 8, comprising the first non-naturally occurring nucleic acid molecule and the second non-naturally occurring nucleic acid molecule in the same non-naturally nucleic acid molecule.
10. The therapeutic combination of any one of claims 4 to 8, comprising the first non-naturally occurring nucleic acid molecule and the second non-naturally occurring nucleic acid molecule in two different non-naturally occurring nucleic acid molecules.
11. The therapeutic combination of any one of claims 4 to 10, wherein the first polynucleotide sequence comprises a polynucleotide sequence having at least 90% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 3.
12. The therapeutic combination of claim 11, wherein the first polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.
13. The therapeutic combination of any one of claims 4 to 12, wherein the second polynucleotide sequence comprises a polynucleotide sequence having at least 90% sequence identity to SEQ ID NO: 5 or SEQ ID NO: 6.

CA 03141003 2021-12-8

14. The therapeutic combination of claim 13, wherein the second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6.
15. The therapeutic combination of any one of claims 1-14, wherein the compound is selected from the group consisting of:

compound 7	compound 8
compound 9	compound 10
compound 11	compound 12

CA 03141003 2021-12-8

compound 101	compound 103
compound 202	compound 203
and	compound 204

or a tautomer or stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof.

5 16. The therapeutic combination of any one of claims 1-14, wherein the compound is selected from the group consisting of:

CA 03141003 2021-12-8

compound 205	compound 207
and	compound 209,

or a tautomer or stereoisomeric form thereof, or a pharmaceutically acceptable salt thereof.

5 17. A kit comprising the therapeutic combination of any one of claims 1-16, and instructions for using the therapeutic combination in treating a hepatitis B virus (HBV) infection in a subject in need thereof.

18. The therapeutic combination of any one of claims 1 to 16 for use in treating a hepatitis B virus (HBV) infection in a subject in need thereof.

10

CA 03141003 2021-12-8



FIG. 1A



FIG. 1B

CA 03141003 2021-12-8



FIG. 2A

FIG. 2B

CA 03141003 2021-12-8



FIG. 3

CA 03141003 2021-12-8